US12448639B2 - Methods for producing heme peroxidases - Google Patents

Methods for producing heme peroxidases

Info

Publication number
US12448639B2
US12448639B2 US17/914,054 US202117914054A US12448639B2 US 12448639 B2 US12448639 B2 US 12448639B2 US 202117914054 A US202117914054 A US 202117914054A US 12448639 B2 US12448639 B2 US 12448639B2
Authority
US
United States
Prior art keywords
heme
refolding
hrp
peroxidase
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/914,054
Other languages
English (en)
Other versions
US20230122727A1 (en
Inventor
Diana HUMER
Oliver Spadiut
Julian EBNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Wien
Original Assignee
Technische Universitaet Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20165131.2A external-priority patent/EP3884956A1/de
Application filed by Technische Universitaet Wien filed Critical Technische Universitaet Wien
Assigned to TECHNISCHE UNIVERSITÄT WIEN reassignment TECHNISCHE UNIVERSITÄT WIEN ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: SPADIUT, OLIVER, HUMER, Diana, EBNER, Julian
Publication of US20230122727A1 publication Critical patent/US20230122727A1/en
Application granted granted Critical
Publication of US12448639B2 publication Critical patent/US12448639B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase

Definitions

  • the present invention relates to methods for producing heme peroxidases.
  • Heme peroxidases are an industrially important class of enzymes with a wide range of applications including immunoassays, diagnostic kits, probe-based assay techniques such as ELISA, EMSA, Western blotting and Southern blotting, waste water treatment, as a reagent in organic synthesis, and potential therapeutic applications.
  • a well known member of the class of heme peroxidases is horseradish peroxidase (HRP) which is commonly used in research and industry.
  • HRP heme peroxidases
  • Recombinant production of heme peroxidases is a desirable alternative as it is a more promising way of manufacturing that guarantees a steady supply of defined enzyme preparations at high quality.
  • recombinant production in E. coli may make it possible to obtain a defined preparation of one isoform with stable biochemical properties while lacking glycosylation and therefore immunogenic potential.
  • HRP contains glycosylations on eight asparagine residues making recombinant production difficult.
  • Wild-type HRP produced from E. coli shows lower stability compared to the plant-derived enzyme.
  • the enzyme can also be translocated to the periplasm by adding a signal sequence but then the yields are even lower and the activity and stability of the enzyme might be compromised by addition of the translocation-tag. Moreover, E. coli is not able to perform post-translational modifications, therefore the enzyme is unglycosylated which results in reduced stability of the protein.
  • the present invention provides a method for producing a heme peroxidase from inclusion bodies (IBs) comprising the steps of:
  • the present invention provides a method for producing a heme peroxidase product comprising producing a heme peroxidase according to the invention.
  • new mutants of HRP are disclosed herein that not only provide improved thermostability and kinetic parameters over wild-type HRP and known HRP mutants, but that are particularly well suited for recombinant production in bacteria; in particular with the method according to the invention.
  • the combination of a strongly improved heme peroxidase and a highly efficient production process is thus enabled.
  • IBs inclusion bodies
  • IBs inclusion bodies
  • inclusion bodies usually contain relatively pure and intact proteins; however, the inclusion bodies need to be solubilized and the proteins need to be refolded into their native structure.
  • IBs are solubilized in a solubilization buffer containing denaturants, such as urea, guanidinium chloride (GdnHCl), or ionic detergents, such as N-lauroylsarcosine.
  • denaturants such as urea, guanidinium chloride (GdnHCl), or ionic detergents, such as N-lauroylsarcosine.
  • reducing agents such as 2-mercaptoethanol ( ⁇ -ME), dithiothreitol (DTT) or 1-monothioglycerol (MTG) are added to reduce non-native inter- and intramolecular disulfide bonds and keep the cysteines in a reduced state.
  • solubilization or “solubilizing” refers to the process necessary to dissolve the IBs, aiming to result in a monomolecular dispersion of the polypeptides with minimal intra- and inter-molecular interactions.
  • a “solubilization buffer” is a buffer that is suitable for purpose of solubilizing the IBs, i.e. typically a buffer with conditions that are sufficiently denaturing for the IBs to be solubilized.
  • Refolding from denatured proteins (solubilized IBs) to active proteins (folded form) typically occurs by removal of denaturant, and is the key step in the efficient recovery of the proteins.
  • the term “refolding” refers to the mechanism during which the denatured protein gains its native or active conformation.
  • refolding buffer refers to a buffer that is suitable for the purpose of refolding, i.e. a buffer that provides conditions allowing the denatured protein to gain its native or active conformation.
  • Refolding efficiency (yield) of refolded protein can be estimated by biological activity, such as enzymatic activity.
  • WO 2014/128726 A2 describes processes of refolding recombinant protein from IBs; however, it is unrelated to peroxidases or heme cofactors.
  • Lin et al. (“High yield production of fungal manganese peroxidases by E. coli through soluble expression, and examination of the activities.” Protein expression and purification 145 (2016): 45-52) describe the expression of fungal manganese peroxidases in soluble form in E. coli . Entirely unrelated to refolding from IBs, a method is described, in which hemin is added to the bacterial cell culture continuously, in order to increase intake of hemin into the cells and to avoid disrupting proper cell activities during protein expression.
  • class I are intracellular peroxidases
  • class II consists of secretory fungal peroxidases
  • class III consists of the secretory plant peroxidases.
  • Class II and III are similar in that their members typically have a heme group, 4 disulfide bridges, and bind two Ca 2+ ions.
  • members of both classes are usually glycosylated in the native state and challenging to express in E. coli . Since in the context of the inventive method, the advantageous effect of distributing the addition of the heme cofactor over a certain period of time i.a.
  • the inventive method can advantageously be used for the refolding of all heme peroxidases.
  • class II and class III heme peroxidases are particularly challenging to recombinantly express, these classes are particularly preferred.
  • the heme peroxidase is therefore a Class II or a Class III heme peroxidase, especially a Class III heme peroxidase.
  • the heme cofactor used in the context of the invention can be heme itself, or any heme precursor or derivative that is incorporated into the apo-peroxidase.
  • hemin the ferric chloride species of heme; CAS [16009-13-5]
  • the heme cofactor is therefore hemin.
  • the sequence of wild-type HRP is known in the art, e.g. from Gajhede et al (“Crystal structure of horseradish peroxidase C at 2.15 ⁇ resolution.” Nature Structural Biology 4.12 (1997): 1032-1038, Protein Data Bank PDB ID 1ATJ) or from UniProt entry P00433. Unless specified otherwise, the residue numbering as used herein refers to the sequence of wild-type HRP as set forth in SEQ ID NO: 1 (the positions P146 and N275 are indicated below in bold).
  • the heme peroxidase comprises a polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 1. Even more preferably, the heme peroxidase is the polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO: 2. Particularly good results were obtained when the heme peroxidase is a polypeptide comprising an amino acid sequence comprising at least two amino acid exchanges compared to SEQ ID NO: 1, wherein said at least two amino acid exchanges are exchanges of the amino acids P146 and N275 of SEQ ID NO: 1.
  • the heme peroxidase comprises an amino acid sequence, which comprises at least one amino acid exchange compared to SEQ ID NO: 1, wherein said at least one amino acid exchange is selected from the group consisting of P146Q, P146A, P146R, P146V, P146E, N275K, N275R, N275D, N275S, N275Q, N275A and N275E.
  • P146Q and N275K are in particular preferred.
  • the amino acid sequence comprises an amino acid exchange selected from the group consisting of P146Q, P146A, P146R, P146V and P146E, especially P146Q, compared to SEQ ID NO: 1. It is further preferred if the amino acid sequence comprises an amino acid exchange selected from the group consisting of N275K, N275R, N275D, N275S, N275Q, N275A and N275E, preferably N275K, compared to SEQ ID NO: 1. It is most preferred, if one of the preferred amino acid exchanges for P146 (especially P146Q) and one of the preferred amino acid exchanges for N275 (especially N275K) are combined.
  • polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 3.
  • Said sequence comprises the amino acid exchanges P146Q and N275K, as well as the amino acid exchanges N13D, N57S, N175S, N255D and N268D with respect to SEQ ID NO: 1 (all marked in bold below).
  • mutant HRP when recombinantly produced, e.g. in E. coli , mutant HRP will typically be produced with an N-terminal methionine residue resulting from the start codon.
  • the HRP mutant described above will therefore typically be recombinantly produced as a protein with the following sequence:
  • the mutants used in the context of the present invention comprise the N-terminal methionine.
  • the amino acid numbering used according to the present invention is applied according to the wild-type sequence lacking the N-terminal methionine (SEQ ID NO: 1); i.e. this numbering is applied to mutants comprising an N-terminal methionine correspondingly, meaning that e.g. in SEQ ID NO: 4 mutation N13D is at (absolute) position no. 14, etc. This is applicable also to further mutant embodiments which carry deletions or insertions.
  • the heme peroxidase preferably is a polypeptide having peroxidase activity and comprising an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 3, wherein said amino acid sequence comprises at least one amino acid exchange compared to SEQ ID NO: 1, wherein said at least one amino acid exchange is an exchange of the amino acid P146 or of the amino acid N275 of SEQ ID NO: 1.
  • the heme peroxidase comprises an amino acid sequence having at least 70%, preferably at least 75%, preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, yet even more preferably at least 95%, especially at least 98%, most preferably at least 99% sequence identity to SEQ ID NO: 3.
  • the amino acid sequence has at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% sequence identity with SEQ ID NO: 3. It is especially preferred, if said amino acid sequence is the sequence as set forth in SEQ ID NO: 3. It is most preferred if the heme peroxidase consists of the amino acid sequence as set forth in SEQ ID NO: 4.
  • amino acid sequence further comprises at least one, preferably at least two, more preferably at least three, even more preferably at least four, especially 5 amino acid exchanges compared to SEQ ID No: 1 selected from the group consisting of N13D, N57S, N175S, N255D, and N268D.
  • the mutations N13D, N57S, N255D and N268D have been disclosed in Capone et al. (“Glyco-variant library of the versatile enzyme horseradish peroxidase.” Glycobiology 24.9 (2014): 852-863) as well as in Humer and Spadiut (“Improving the performance of horseradish peroxidase by site-directed mutagenesis.” International Journal of Molecular Sciences 20.4 (2019): 916). Unrelated thereto, and only in the context of expression in yeast, the mutation N175S has been disclosed in Morawski et al. (“Functional expression and stabilization of horseradish peroxidase by directed evolution in Saccharomyces cerevisiae .” Biotechnology and Bioengineering 76.2 (2001): 99-107).
  • the amino acid sequence therefore further comprises the amino acid exchange T110V or K 232N compared to SEQ ID NO: 1.
  • peroxidase activity preferably means activity for at least one of the substrates 3,3′,5,5′-tetramethylbenzidine (TMB), 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), or hydrogen peroxide (H 2 O 2 ).
  • TMB 3,3′,5,5′-tetramethylbenzidine
  • ABTS 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
  • hydrogen peroxide H 2 O 2
  • the heme peroxidase has a peroxidase activity corresponding to a kcat/Km value for the substrate TMB of at least 0.01 mM ⁇ 1 s ⁇ 1 , preferably at least 0.1 mM ⁇ 1 s ⁇ 1 , more preferably at least 1 mM ⁇ 1 s ⁇ 1 , even more preferably at least 10 mM ⁇ 1 s ⁇ 1 , even more preferably at least 20 mM ⁇ 1 s ⁇ 1 , even more preferably at least 100 mM ⁇ 1 s ⁇ 1 , yet even more preferably at least 1000 mM ⁇ 1 s ⁇ 1 , yet even more preferably at least 10000 mM ⁇ 1 s ⁇ 1 , especially at least 20000 mM ⁇ 1 s ⁇ 1 , when measured in 50 mM phosphate-citrate buffer containing 1 mM H 2 O 2 at pH 5 and 30° C.
  • the heme peroxidase has an increased thermostability with respect to wild-type HRP.
  • a polypeptide consisting of said amino acid sequence has an increased thermostability with respect to a polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2, preferably SEQ ID NO: 2.
  • a methionine residue can be appended to the N-terminus of said amino acid sequence with a certain % sequence identity to SEQ ID NO: 3 so that it can be recombinantly produced in E. coli ; i.e.
  • a polypeptide consisting of an N-terminal methionine residue followed by said amino acid sequence has an increased thermostability with respect to a polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO: 2).
  • the polypeptides can be produced and measured under the same conditions. “Increased thermostability” preferably means a longer half-life when incubated at 60° C. in a buffer consisting of 20 mM BisTris/HCl pH 7, 7% glycerol and 500 mM NaCl.
  • the heme peroxidase and/or a polypeptide consisting of the amino acid sequence with a certain % sequence identity to SEQ ID NO: 3 as defined above has a half-life at 60° C. of at least 0.5 hours, preferably at least 1 hour, more preferably at least 2 hours, even more preferably at least 4 hours, most preferably at least 6 hours in a buffer consisting of 20 mM BisTris/HCl pH 7, 7% glycerol and 500 mM NaCl, as measured by the residual peroxidase activity with 7 mM ABTS in 50 mM phosphate-citrate buffer containing 1 mM H 2 O 2 at pH 5 and 30° C.
  • the inventive method for producing the heme peroxidase it was surprisingly found that spreading out the addition of the heme cofactor to the refolding mix over a certain period of time leads to superior results compared to adding the cofactor all at once in one batch (see Example 3; comparison of Tables 5 and 6). Slower additions of the heme cofactor are generally preferred.
  • the addition of the heme cofactor to the refolding mix is preferably distributed over a time period of at least 1 hour, but even longer time periods are even more preferred. In increasing order of preference, the time period is at least 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, especially at least 10 hours.
  • the heme cofactor addition involves at least 2 (but preferably at least 3, more preferably at least 4, even more preferably at least 6, most preferably at least 10) increases of heme cofactor concentration, wherein the first and the last increase are separated at least by the time period specified above (e.g. at least 2 heme cofactor concentration increases separated by at least 1 hour, preferably by at least 4 hours, especially at least 10 hours).
  • This can be achieved both by multiple discrete steps of heme cofactor concentration increases (the total amount of heme cofactor addition is divided into multiple smaller doses) or by a continuous supply of heme cofactor, or by a combination of the two. It is especially advantageous if the total amount of heme cofactor added to the refolding mix is distributed evenly.
  • the heme cofactor is added to the refolding mix at a rate between 0.1 and 10 ⁇ mol/L per hour, preferably between 0.2 and 5 ⁇ mol/L per hour, even more preferably between 0.5 and 3 ⁇ mol/L per hour, yet even more preferably between 1 and 2.5 ⁇ mol/L per hour, especially between 1.4 and 1.8 ⁇ mol/L per hour.
  • the heme cofactor is added at a rate between 0.01 and 1 molar equivalents per hour, preferably between 0.02 and 0.5 molar equivalents per hour, more preferably between 0.05 and 0.2 molar equivalents per hour.
  • the refolding mix therefore is incubated for at least 1 hour, preferably at least 2 hours, even more preferably at least 4 hours, especially at least 8 hours prior to the addition of the heme cofactor.
  • This does not mean that no heme cofactor can be present at all during this incubation time; in the context of this embodiment it is merely required that heme cofactor is added to the refolding mix after the specified time period.
  • At least 1 ⁇ mol/L, preferably at least 4 ⁇ mol/L, even more preferably at least 10 ⁇ mol/L, especially at least 20 ⁇ mol/L of the heme cofactor is added to the refolding mix.
  • At least 0.25, preferably at least 0.5, even more preferably at least 1, especially at least 2 molar equivalents of the heme cofactor with respect to the heme peroxidase are added to the refolding mix.
  • between 0.25 and 10, preferably between 0.5 and 5, even more preferably between 1 and 4, especially between 1 and 2 molar equivalents of the heme cofactor with respect to the heme peroxidase may be added to the refolding mix.
  • the IBs for use in the method according to the invention, standard techniques known in the art can be used.
  • the skilled person is familiar with methods to recombinantly express a certain heme peroxidase in suitable host cells, e.g. E. coli , and obtain IBs containing said heme peroxidase.
  • the heme peroxidase in the form of IBs is provided by the steps of: culturing host cells expressing a gene encoding the heme peroxidase; and obtaining IBs from said host cells.
  • the host cells are prokaryotic cells, preferably E. coli cells.
  • the method according to the invention is well suited to produce heme peroxidases in large quantities.
  • the inventive method is scalable to larger culturing volumes and thus larger amounts of produced heme peroxidase.
  • the cells are therefore cultured in a volume of at least 2 L, preferably at least 5 L, more preferably at least 20 L, even more preferably at least 50 L, especially at least 100 L.
  • solubilizing the IBs comprises incubating the IBs in a solubilization buffer.
  • a solubilization buffer has a pH of at least 8, preferably at least 8.5, more preferably at least 9.0, even more preferably at least 9.5.
  • the solubilization buffer has a pH between 8 and 12.5, preferably between 8.5 and 11.5, more preferably between 9 and 11, even more preferably between 9.5 and 10.5.
  • the solubilization buffer used for solubilizing the IBs contains a reducing agent.
  • a reducing agent In the context of the present invention, it was found that certain concentrations of reducing agents lead to particularly advantageous results (see in particular Example 2, DoE1-3; Example 3, Reactor runs 1-4).
  • the reducing agent is DTT.
  • other reducing agents can be used as well.
  • the skilled person is familiar with other reducing agents commonly used for IB solubilization, e.g. ⁇ -ME, TCEP (tris(2-carboxyethyl)phosphine), cysteine, etc. All of these reducing agents are also preferred in the context of the inventive method.
  • the redox conditions in the solubilization buffer correspond to a DTT concentration between 1 and 50 mmol/L DTT, preferably between 2 and 25 mmol/L, more preferably between 4 and 15 mmol/L, especially between 6 and 8 mmol/L.
  • the term “redox conditions” refers to the reduction potential and “correspond to” means that either DTT is present in the amount indicated or that another reducing agent (such as e.g. ⁇ -ME, TCEP or cysteine) is present in a concentration which leads to the same reduction potential, as measured in a solution of 50 mM glycine, 6 M urea in water at pH 10, at 25° C.
  • the reduction potential of the solubilization buffer is between ⁇ 150 mV and ⁇ 500 mV, preferably between ⁇ 200 mV and ⁇ 450 mV, more preferably between ⁇ 250 mV and ⁇ 400 mV, even more preferably between ⁇ 280 mV and ⁇ 370 mV, yet even more preferably between ⁇ 300 mV and ⁇ 340 mV, most preferably between ⁇ 310 mV and ⁇ 330 mV.
  • the reduction potential is preferably measured at a temperature of 25° C. and a pressure of 101.300 Pa. The skilled person is familiar with methods to measure the reduction potential.
  • the measurement of the reduction potential is carried out with an EasyFerm Plus ORP Arc 425, connected to the Lucullus process system, preferably as described in Example 3.
  • the measurement can be carried out as described in the standard ASTM D1498-14 (“Standard Test Method for Oxidation—Reduction Potential of Water”, ASTM International, West Conshohocken, PA, 2014, www.astm.org).
  • the reducing agent contains thiol groups.
  • the concentration of thiol groups in the solubilization buffer is between 2 and 100 mmol/L, preferably between 4 and 50 mmol/L, more preferably between 8 and 30 mmol/L, especially between 12 and 16 mmol/L.
  • the concentration of thiol groups in the solubilization buffer preferably is determined based on the concentration of thiol-containing substances added to the solubilization buffer (e.g. DTT contains 2 thiol groups per molecule; a concentration of 1 mmol/L DTT therefore corresponds to a concentration of 2 mmol/L thiol groups).
  • the concentration of thiol groups can also be determined experimentally.
  • the concentration of thiol groups in the solubilization buffer is measured using Ellman's reagent.
  • Ellman's reagent (5,5′-dithiobis-(2-nitrobenzoic acid) or DTNB) is a chemical used to quantify the number or concentration of thiol groups in a sample.
  • the skilled person is familiar with how to perform measurements using Ellman's reagent.
  • the measurement is carried out as described in Simpson (“Estimation of Free Thiols and Disulfide Bonds Using Ellman's Reagent.” CSH Protocols 2008 (2008): pdb-prot4699).
  • the solubilization buffer typically contains a denaturing agent.
  • a denaturing agent e.g. urea or GdnHCl.
  • the solubilization buffer contains urea, preferably in a concentration of at least 4 mol/L, more preferably at least 5 mol/L, even more preferably at least 6 mol/L.
  • the solubilization buffer contains between 4 mol/L and 8 mol/L urea, preferably between 5 mol/L and 7 mol/L, especially between 5.5 and 6.5 mol/L.
  • the IBs are incubated in the solubilization buffer for at least 5 minutes, preferably at least 10 minutes, more preferably at least 15 minutes, especially at least 30 minutes.
  • the IBs are incubated in said solubilization buffer at a temperature between 4° C. and 40° C., preferably between 10° C. and 35° C., even more preferably between 20° C. and 25° C.
  • the solubilized IBs are mixed with the refolding buffer in a ratio between 1:5 v/v and 1:250 (solubilized IBs: refolding buffer), preferably between 1:10 and 1:100, even more preferably between 1:20 and 1:80, especially between 1:30 and 1:60.
  • the inventive method is particularly well suited to produce the heme peroxidase in large amounts. Therefore, the refolding is preferably carried out in a volume of at least 5 L, preferably at least 10 L, more preferably at least 25 L, even more preferably at least 100 L.
  • the refolding mix preferably has a volume of at least 5 L, preferably at least 10 L, more preferably at least 25 L, even more preferably at least 100 L.
  • the refolding buffer has a pH of at least 8, preferably at least 8.5, more preferably at least 9, even more preferably at least 9.5. In particular, it is preferred if the refolding buffer has a pH between 8 and 12.5, preferably between 8.5 and 11.5, more preferably between 9 and 11, even more preferably between 9.5 and 10.5.
  • the difference in the pH between the solubilization buffer and the refolding buffer is less than 2 pH increments, preferably less than 1 pH increment, more preferably less than 0.5 pH increments, even more preferably less than 0.2 pH increments, especially less than 0.1 pH increments.
  • the pH of the solubilization buffer is 10
  • the pH of the refolding buffer is preferably between 9 and 11 (i.e. the difference is less than 1 pH increment), more preferably between 9.5 and 10.5 (the difference is less than 0.5 pH increments), etc.
  • the refolding buffer used in the context of the inventive method contains an oxidizing agent.
  • oxidizing agents that are commonly used in refolding buffers, e.g. glutathione disulfide (GSSG) or cystine, which are all preferred in the context of the inventive method.
  • GSSG glutathione disulfide
  • cystine cystine
  • the refolding buffer has redox conditions corresponding to a GSSG concentration between 0.2 and 6 mM GSSG, preferably between 0.4 and 4 mM GSSG, more preferably between 0.8 and 2.5 mM GSSG, especially between 1.1 and 1.6 mM GSSG.
  • redox conditions refers to the reduction potential and “correspond to” means that either GSSG is present in the amount indicated or that another oxidizing agent (such as cystine) is present in a concentration which leads to the same reduction potential, when measured in a solution of 20 mM glycine, 2 mM CaCl 2 , 2 M Urea, 7% v/v glycerol at pH 10, at 25° C.
  • the refolding buffer has a reduction potential between 50 mV and 110 mV, preferably between 60 mV and 100 mV, more preferably between 65 mV and 95 mV, most preferably between 70 mV and 90 mV.
  • the reduction potential is measured as described herein above in the context of the solubilization buffer.
  • the refolding buffer contains a denaturing agent.
  • the same denaturing agents are preferred as for the solubilization buffer, albeit in lower concentrations.
  • the refolding buffer contains between 0.5 and 3 mol/L urea, preferably between 1 mol/L and 2.7 mol/L, even more preferably between 1.5 mol/L and 2.4 mol/L, especially between 1.8 and 2.2 mol/L.
  • the refolding mix contains both DTT and GSSG.
  • the molar ratio between DTT and GSSG in the refolding mix is between 1:2 (DTT:GSSG) and 1:30, preferably between 1:3 and 1:20, even more preferably between 1:4 and 1:15, especially between 1:6 and 1:8.
  • DTT:GSSG 1:2 (DTT:GSSG) and 1:30, preferably between 1:3 and 1:20, even more preferably between 1:4 and 1:15, especially between 1:6 and 1:8.
  • the refolding mix has a reduction potential between ⁇ 105 mV and 135 mV, preferably between ⁇ 90 mV and 105 mV, even more preferably between ⁇ 80 mV and 80 mV, yet even more preferably between ⁇ 70 mV and 60 mV, most preferably between ⁇ 60 mV and 50 mV.
  • said reduction potential is measured as described above in the context of the solubilization buffer.
  • the reduction potential is measured immediately upon mixing the solubilization buffer and the refolding buffer, before the addition of the heme cofactor.
  • the inventive method preferably further comprises the step of adding salt to the refolding mix.
  • the concentration of the salt is between 2 mol/L and 12 mol/L, preferably between 4 mol/L and 10 mol/L, even more preferably between 4.5 mol/L and 8 mol/L.
  • the salt is sodium chloride, preferably in a concentration between 0.5 and 6 mol/L, more preferably between 1.5 and 5.5 mol/L, even more preferably between 2.5 and 5 mol/L, especially between 3.5 and 4.5 mol/L.
  • the salt is ammonium sulfate, preferably in a concentration between 0.25 and 1.5 mol/L, preferably between 0.5 and 1.4 mol/L, even more preferably between 0.8 and 1.2 mol/L.
  • Any salts commonly used for salting out proteins can be used in the context of the inventive method. The skilled person is familiar with such salts, e.g.
  • KCl K 2 CO 3 , CaCl 2
  • NH 4 Cl Na 2 SO 4
  • NaOAc NaOAc
  • the salt is added to the refolding mix to an ionic strength between 0.5 and 6 mol/L, preferably between 1.5 and 5 mol/L, even more preferably between 2.5 and 4.5 mol/L, especially between 3.5 and 4.5 mol/L.
  • the salting-out strength of a particular salt can also be determined by its position in the so-called Hofmeister series (also called “lyotropic series”).
  • the Hofmeister series is a classification of ions in order of their ability to salt out or salt in proteins (exemplary anions in order of decreasing salting out strength are SO 4 2 ⁇ >HPO 4 2 ⁇ >OAc ⁇ >Cl ⁇ >NO 3 ⁇ >I ⁇ >SCN ⁇ ; equally for cations: NH 4 + >K + >Na + >Li + >Mg 2 + >Ca 2 + >guanidinium).
  • the salt has a salting-out strength between ammonium sulfate and sodium chloride as determined by its position in the Hofmeister series, preferably wherein the concentration of the salt is between 1.25 and 6 mol/L, more preferably between 0.5 and 5 mol/L, even more preferably between 1.0 and 4.5 mol/L, most preferably between 1.5 and 4 mol/L.
  • the salt has a weaker salting-out strength than sodium chloride as determined by its position in the Hofmeister series, preferably wherein the concentration of the salt is at least 2 mol/L, preferably at least 4 mol/L, more preferably at least 4.5 mol/L.
  • a first salt is considered to have a higher/lower salting out strength than a second salt, if both the first salt's cation and its anion have a higher/lower salting out strength than the cation and anion of the second salt as determined by the Hofmeister series.
  • the inventive method further comprises a centrifugation step for removing impurities from the refolded heme peroxidase.
  • the inventive method may further comprise a filtration step for removing impurities from the refolded heme peroxidase.
  • the method according to the invention further comprises the step of purifying the refolded heme peroxidase. It has been found to be particularly advantageous if the heme peroxidase is in its holo-form during purification; preferably, the heme peroxidase is therefore purified after the heme cofactor has been added to the refolding mix.
  • heme peroxidase For the purpose of purification, frequently purification tags, such as polyhistidine-tags (typically consisting of a number of histidine residues, e.g. 6-10, often appended to the N- or C-terminus of the protein) are used in the art. Such tags can also be used in the context of the present invention. However, it is preferred if the heme peroxidase does not comprise a purification tag. In particular it is preferred if the heme peroxidase does not comprise a polyhistidine-tag.
  • the heme peroxidase is purified by chromatography, especially by hydrophobic interaction chromatography (HIC).
  • HIC hydrophobic interaction chromatography
  • this type of purification leads to surprisingly good results, in particular to high final concentrations, excellent purity and high activity (see Example 4).
  • HIC is in particular well suited in combination with a salt precipitation step for removing impurities, as described herein above, because HIC typically involves binding conditions with high salt concentrations.
  • the high salt concentration can therefore precipitate impurities as well as excess heme cofactor while the correctly folded heme peroxidase remains in solution and can directly be used as the load for HIC.
  • the skilled person is familiar with how to perform HIC; preferably it is performed as described in Example 4. It is especially preferred if the stationary phase is a butyl sepharose resin.
  • heme peroxidase product can be any product obtained from a heme peroxidase produced by the method according to the invention, e.g. a conjugate of the heme peroxidase to another molecule, e.g. a protein or an otherwise modified or derivatized heme peroxidase, e.g. a heme peroxidase linked to a solid carrier etc.
  • the “heme peroxidase product” can also be any type of commercial product containing a heme peroxidase (or modified/derivatized/conjugated heme peroxidase), e.g. a composition containing such a heme peroxidase (e.g. in solution or in lyophilized form), or a container containing such a composition or any type of packaged product, such as a kit, containing such a container.
  • HRP heme peroxidases
  • conjugates are e.g. useful in techniques such as western blots, ELISA and immunohistochemistry.
  • One type of conjugate that is widely used is a conjugate with an antibody or another binding protein. In this case, a detectable signal can be generated at the site where the binding protein is bound to its target by adding a substrate of HRP.
  • HRP conjugates that are frequently used include HRP-streptavidin conjugates (e.g.
  • HRP-protein A, G or L conjugates proteins A, G and L bind to immunoglobulins and are thus useful for detecting primary antibodies, e.g. in ELISA, ELISPOT, IHC, or Western blotting.
  • kits for conjugating heme peroxidases such as HRP to proteins of interest; e.g. HRP Conjugation Kit/HRP Labeling Kit ab102890 from the company Abcam, LYNX Rapid HRP Antibody Conjugation Kit from the company Bio-Rad (product code LNK001P), or EZ-Link Plus Activated Peroxidase Kit from the company Thermo Fisher Scientific (catalogue number 31489).
  • the purpose of such kits is typically to enable the user to conjugate the peroxidase to any protein of interest, e.g. an antibody.
  • kits may comprise the heme peroxidase in activated form (for direct reaction with another protein) or the kit may comprise the heme peroxidase and a suitable crosslinker for conjugation by the user.
  • the crosslinker comprises one, especially two reactive groups selected from the group consisting of NHS ester, succinimidyl ester, imidoester, difluoro, haloacetyl, maleimide, pyridyldithiol and hydrazide.
  • the crosslinker may be a bifunctional PEG linker having a maleimide group and an active ester group, e.g. Maleimide-PEG 8 -succinimidyl ester (CAS Number 756525-93-6, e.g. commercially available from Sigma-Aldrich cat. no. 746207).
  • the heme peroxidase produced according to the inventive method may be a polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO: 4.
  • said heme peroxidase may also be a polypeptide having peroxidase activity, as defined herein above, and further comprising the amino acid sequence of a further protein.
  • Fusion proteins can be obtained by known methods, e.g. by generating a genetic fusion (joining the nucleic acid sequence encoding the heme peroxidase to a nucleic acid sequence encoding the further protein protein, preferably with the inclusion of a linker sequence between the two proteins).
  • Said further protein may be streptavidin.
  • said further protein is an antibody-binding protein, preferably protein A, protein G or protein L.
  • the heme peroxidase produced according to the inventive method comprises an amino acid sequence of a binding protein.
  • Said binding protein may be any protein that can act as an agent to bind to a molecule of interest, e.g. to detect a specific protein or another molecule.
  • Preferably said binding protein is an antibody.
  • said binding protein is an antibody fragment, preferably a single-chain variable fragment (scFv) or an antigen-binding fragment (Fab).
  • said binding protein is an antibody mimetic, preferably selected from the group consisting of adnectins, affibodies, anticalins, DARPins, engineered Kunitz-type inhibitors, and monobodies.
  • adnectins preferably selected from the group consisting of adnectins, affibodies, anticalins, DARPins, engineered Kunitz-type inhibitors, and monobodies.
  • suitable binding proteins are known from the art, e.g. from Gebauer and Skerra (“Engineered protein scaffolds as next-generation antibody therapeutics.” Current opinion in chemical biology 13.3 (2009): 245-255).
  • the heme peroxidase is conjugated to an antibody mimetic, preferably selected from the group consisting of adnectins, affibodies, anticalins, DARPins, engineered Kunitz-type inhibitors, and monobodies.
  • the heme peroxidase is conjugated to an antibody binding protein, preferably protein A, protein G, or protein L.
  • the heme peroxidase is conjugated to a further protein, preferably streptavidin.
  • Conjugates between heme peroxidases and other proteins can be obtained by conjugation reactions, which are known to the skilled person, e.g. by chemical crosslinking.
  • the heme peroxidase and the other protein can be linked together by a chemical crosslinker, forming a stable, preferably covalent, link between the two molecules.
  • Such methods often referred to as bioconjugation, are known in the art.
  • a large number of suitable methods can e.g. be found in the book Hermanson, Greg T. Bioconjugate Techniques. Academic press, 2013.
  • the inventive method for producing the heme peroxidase product may comprise further purification, concentration, or other processing of the heme peroxidase.
  • the method further comprises the step of purifying the heme peroxidase or the heme peroxidase conjugate.
  • the heme peroxidase in this context, may already have been derivatized or otherwise modified.
  • the method further comprises the step of freezing the heme peroxidase or the heme peroxidase conjugate.
  • the method preferably further comprises the step of lyophilizing the heme peroxidase or the heme peroxidase conjugate.
  • the heme peroxidase product may also be a composition comprising the heme peroxidase produced by the method according to the invention or a product (e.g. a container) containing said composition.
  • a product e.g. a container
  • excipients are added to said composition.
  • excipients may, for instance, further increase the stability of the heme peroxidase in storage, ensure an even longer shelf-life and a stable level of biological activity.
  • Preferred excipients include pH buffering agents, stabilizing agents, bulking agents, tonicity modifiers and the like. Especially preferred are excipients that are suitable for use in the context of lyophilization.
  • the composition preferably contains a pH buffering agent, preferably selected from the group consisting of glycine, histidine, glutamate, succinate, phosphate, acetate, and aspartate. It is further preferred that the composition comprises a bulking agent, preferably selected from the group consisting of mannitol, glycine, sucrose, dextran, polyvinylpyrolidone, carboxymethylcellulose, lactose, sorbitol, trehalose, or xylitol.
  • a pH buffering agent preferably selected from the group consisting of glycine, histidine, glutamate, succinate, phosphate, acetate, and aspartate.
  • the composition comprises a bulking agent, preferably selected from the group consisting of mannitol, glycine, sucrose, dextran, polyvinylpyrolidone, carboxymethylcellulose, lactose, sorbitol, trehalose, or xylitol.
  • the composition preferably comprises a stabilizing agent selected from the group consisting of sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose, gentiobiose, isomaltose, arabinose, glucosamine, fructose, mannitol, sorbitol, glycine, arginine HCL, poly-hydroxy compounds, including polysaccharides such as dextran, starch, hydroxyethyl starch, cyclodextrins, N-methyl pyrollidene, cellulose and hyaluronic acid, sodium chloride.
  • a stabilizing agent selected from the group consisting of sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose, gentiobiose, isomaltose, arabinose, glucosamine, fructose, mannitol
  • the composition may further include a surfactant, preferably selected from the group consisting of sodium lauryl sulfate, dioctyl sodium sulfosuccinate, dioctyl sodium sulfonate, chenodeoxycholic acid, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, glycodeoxycholic acid sodium salt, benzalkonium chloride or benzethonium chloride, cetylpyridinium chloride monohydrate, hexadecyltrimethylammonium bromide, CHAPS, CHAPSO, SB3-10, SB3-12, digitonin, Triton X-100, Triton X-114, lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 40, 50 and 60, glycerol monostearate,
  • the composition comprises at least 0.01 mg, preferably at least 0.1 mg, more preferably at least 1 mg, even more preferably at least 5 mg, especially at least 10 mg of the heme peroxidase produced according to the invention. It is further preferred if the composition contains the heme peroxidase in a concentration of at least 0.0001% (weight per weight, w/w), preferably at least 0.001% w/w, more preferably at least 0.01% w/w, even more preferably at least 0.1% w/w, yet even more preferably at least 1% w/w, especially at least 10% w/w.
  • the composition is a solid composition (at 25° C. and at atmospheric pressure), preferably a lyophilized composition.
  • the composition is a liquid composition (at 25° C. and at atmospheric pressure).
  • the composition contains the heme peroxidase produced according to the invention in a concentration of at least 0.001 mg/mL, preferably at least 0.01 mg/mL, more preferably at least 0.1 mg/mL, yet even more preferably at least 0.5 mg/mL, most preferably at least 2 mg/mL.
  • the composition is substantially free of DNA, especially dsDNA.
  • the composition contains less than 1 ⁇ g/g, preferably less than 100 ng/g, more preferably less than 10 ng/g, most preferably less than 1 ng/g DNA.
  • the DNA concentration can be determined by fluorometry using the dye SYBR Green I (N′,N′-dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine).
  • SYBR Green I N′,N′-dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine.
  • the skilled person is familiar with the measurement of DNA concentrations
  • the heme peroxidase product may find use in a variety of therapeutic applications, for instance in targeted cancer treatment.
  • the heme peroxidase product is therefore a pharmaceutical composition, preferably comprising one or more excipients, which are pharmaceutically acceptable for administration to an individual, especially a mammal, in particular a human.
  • excipients are known to the person skilled in the art, for example water (especially water for injection), saline, Ringer's solution, dextrose solution, buffers, Hank solution, vesicle forming compounds (e.g.
  • lipids lipids
  • fixed oils ethyl oleate
  • 5% dextrose in saline substances that enhance isotonicity and chemical stability
  • buffers and preservatives include any compound that does not induce the production of antibodies when administered to a patient that are harmful for the patient. Examples are well tolerable proteins, polysaccharides, polylactic acids, polyglycolic acid, polymeric amino acids and amino acid copolymers.
  • This pharmaceutical composition is preferably suitable for parenteral administration, in particular intravenous administration.
  • the pharmaceutical composition may be provided in injectable dosage unit form, e.g. as a solution, suspension or emulsion, formulated in conjunction with the above-defined pharmaceutically acceptable excipients. All preferred embodiments listed above for the composition in general (in particular related to concentrations and amounts of the heme peroxidase), are also preferred when the heme peroxidase product is a pharmaceutical composition.
  • the heme peroxidase may be part of an enzyme-prodrug system.
  • Enzyme-prodrug systems comprising heme peroxidases such as HRP are known in the art, in particular for the treatment of cancer (see e.g. Tupper et al. “In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer.” Cancer Gene Therapy 17.6 (2010): 420-428).
  • targeted cancer treatment may involve an enzyme-prodrug system that comprises HRP together with Indole acetic acid (IAA), wherein HRP oxidizes Indole acetic acid (IAA), which then decreases the viability of carcinoma cells.
  • IAA Indole acetic acid
  • the heme peroxidase product produced according to the invention may in particular find use in antibody directed enzyme prodrug therapy (ADEPT; see e.g. Bagshawe “Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.” Expert Review of Anticancer Therapy 6.10 (2006): 1421-1431).
  • ADEPT antibody directed enzyme prodrug therapy
  • the principle of ADEPT is typically to use an antibody directed at a tumor-associated antigen to localize an enzyme (such as e.g. HRP) to tumor sites.
  • a prodrug can be given to the patient which is then converted into its activated species location-specifically.
  • the nucleic acid molecule encoding the heme peroxidase may also find use in therapy, in particular in gene therapy such as gene-directed enzyme prodrug therapy (GDEPT).
  • GDEPT gene-directed enzyme prodrug therapy
  • the inventive method preferably further comprises the step of immobilizing the heme peroxidase or heme peroxidase conjugate on a solid carrier.
  • enzyme immobilization allows a particularly high storage stability, enhanced reusability, reduction of the operational process cost, etc.
  • Heme peroxidases immobilized on solid carriers and their industrial applications are known in the art, see e.g. Tatsumi, et al. (“Removal of chlorophenols from wastewater by immobilized horseradish peroxidase.” Biotechnology and Bioengineering 51.1 (1996): 126-130) and Sarno and Monno (“Immobilization of Horseradish Peroxidase on Fe 3 O 4 /Au_GO Nanoparticles to Remove 4-chlorophenols from Waste Water.” Chemical Engineering Transactions 73 (2019): 217-222).
  • Nanomaterials are particularly suitable as solid carriers because of their specific surface area and effective enzyme loading. In the context of this embodiment, it is therefore preferred if the solid carrier is a nanoparticle.
  • a “nanoparticle” as used herein preferably is a particle of any shape with all three dimensions in the 1 ⁇ 10 ⁇ 2 to 1 ⁇ 10 ⁇ 6 m range, even more preferably in the 1 ⁇ 10 ⁇ 9 to 1 ⁇ 10 ⁇ 7 m range.
  • the nanoparticle may e.g. be a magnetite (Fe 3 O 4 ) nanoparticle or a gold nanoparticle.
  • magnetic nanoparticles since they offer the additional advantage of easy separation by applying a magnetic field.
  • Further preferred examples of solid carriers are nanofibers, carbon/polyvinyl materials, carbon nanotubes, nanowires, nanorods, nanocrystals, mesoporous silica and composite materials.
  • the solid carrier is a membrane, in particular a synthetic membrane such as polymeric membrane.
  • Membranes comprising immobilized heme peroxidases, methods of producing such membranes as well as applications of such membranes are known in the art, e.g. fromieriva et al. (“Application of immobilized horseradish peroxidase onto modified acrylonitrile copolymer membrane in removing of phenol from water.” International journal of biological macromolecules 44.2 (2009): 190-194).
  • the heme peroxidase product is a kit.
  • the inventive method therefore preferably further comprises the step of packaging the heme peroxidase or the heme peroxidase conjugate in a kit. It is preferred if further components selected from buffers, reagents, instructions manuals are added to the kit.
  • the heme peroxidase or the heme peroxidase conjugate may be provided in the kit in lyophilized form. In an alternative preferred embodiment, the heme peroxidase or the heme peroxidase conjugate is provided in solution.
  • the heme peroxidase produced according to the inventive method may further find use as a reactant for coupled enzyme assays.
  • an enzyme of interest e.g. glucose oxidase
  • produces H 2 O 2 which then can be utilized by the heme peroxidase (see e.g. Aumiller et al. “Coupled enzyme reactions performed in heterogeneous reaction media: experiments and modeling for glucose oxidase and horseradish peroxidase in a PEG/citrate aqueous two-phase system.” The Journal of Physical Chemistry B 118.9 (2014): 2506-2517).
  • an enzyme that produces H 2 O 2 is therefore added to the kit.
  • the heme peroxidase produced according to the invention may be further used as a reactant for polymer crosslinking.
  • HRP has successfully been used in the art for the enzymatic crosslinking of dextran-tyramine conjugates for the preparation of hydrogels, e.g. as 3D scaffolds for cartilage tissue engineering applications (Jin et al. “Enzymatically crosslinked dextran-tyramine hydrogels as injectable scaffolds for cartilage tissue engineering.” Tissue Engineering Part A 16.8 (2010): 2429-2440).
  • Percent (%) amino acid sequence identity “X % sequence identity” or “X % identical” (such as “70% sequence identity” or “70% identical”) with respect to a reference polypeptide or protein sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
  • Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2, Megalign (DNASTAR) or the “needle” pairwise sequence alignment application of the EMBOSS software package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are calculated using the sequence alignment of the computer programme “needle” of the EMBOSS software package (publicly available from European Molecular Biology Laboratory; Rice et al., EMBOSS: the European Molecular Biology Open Software Suite, Trends Genet. 2000 June; 16(6):276-7, PMID: 10827456).
  • the needle programme runs on many widely-used UNIX operating systems, such as Linux.
  • the needle programme is preferably run with the following parameters: Commandline: needle -auto -stdout -asequence SEQUENCE_FILE_A -bsequence SEQUENCE_FILE_B -datafile EBLOSUM62 -gapopen 10.0 -gapextend 0.5 -endopen 10.0 -endextend 0.5 -aformat3 pair -sprotein1 -sprotein2 (Align_format: pair Report_file: stdout)
  • the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program needle in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.
  • Y is the entire sequence length of B (i.e. the entire number of amino acid residues in B). Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the needle computer program.
  • Percentages (%) as used herein correspond to weight per volume (w/v) unless specified as weight per weight (w/w) or otherwise.
  • Embodiment 1 Method for producing a heme peroxidase from inclusion bodies (IBs) comprising the steps of:
  • Embodiment 2 Method according to embodiment 1, wherein the addition of the heme cofactor to the refolding mix is distributed over a time period of at least 2 hours, preferably at least 3 hours, more preferably at least 6 hours, even more preferably at least 8 hours, especially at least 10 hours.
  • Embodiment 3 Method according to embodiment 1 or 2, wherein the heme cofactor is added to the refolding mix as a continuous feed.
  • Embodiment 4 Method according to any one of embodiments 1 to 3, wherein the heme cofactor is added to the refolding mix at a rate between 0.1 and 10 ⁇ mol/L per hour, preferably between 0.2 and 5 ⁇ mol/L per hour, even more preferably between 0.5 and 3 ⁇ mol/L per hour, yet even more preferably between 1 and 2.5 ⁇ mol/L per hour, especially between 1.4 and 1.8 ⁇ mol/L per hour.
  • Embodiment 5 Method according to any one of embodiments 1 to 4, wherein the refolding mix is incubated for at least 1 hour, preferably at least 2 hours, even more preferably at least 4 hours, especially at least 8 hours prior to the addition of the heme cofactor.
  • Embodiment 6 Method according to any one of embodiments 1 to 5, wherein at least 1 ⁇ mol/L, preferably at least 4 ⁇ mol/L, even more preferably at least 10 ⁇ mol/L, especially at least 20 ⁇ mol/L of the heme cofactor is added to the refolding mix.
  • Embodiment 7 Method according to any one of embodiments 1 to 6, wherein between 1 ⁇ mol/L and 200 ⁇ mol/L, preferably between 4 ⁇ mol/L and 100 ⁇ mol/L, even more preferably between 10 ⁇ mol/L and 50 ⁇ mol/L, especially between 15 ⁇ mol/L and 25 ⁇ mol/L of the heme cofactor is added to the refolding mix.
  • Embodiment 8 Method according to any one of embodiments 1 to 7, wherein at least 0.25, preferably at least 0.5, even more preferably at least 1, especially at least 2 molar equivalents of the heme cofactor with respect to the heme peroxidase are added to the refolding mix.
  • Embodiment 9 Method according to any one of embodiments 1 to 8, wherein between 0.25 and 10, preferably between 0.5 and 5, even more preferably between 1 and 4, especially between 1 and 2 molar equivalents of the heme cofactor with respect to the heme peroxidase are added to the refolding mix.
  • Embodiment 10 Method according to any one of embodiments 1 to 9, wherein the heme peroxidase is a Class II or a Class III heme peroxidase, preferably a Class III heme peroxidase.
  • Embodiment 11 Method according to any one of embodiments 1 to 10, wherein the heme peroxidase is horseradish peroxidase (HRP).
  • HRP horseradish peroxidase
  • Embodiment 12 Method according to any one of embodiments 1 to 11, wherein the heme peroxidase does not comprise a purification tag, especially a polyhistidine-tag.
  • Embodiment 13 Method according to any one of embodiments 1 to 12, wherein the heme peroxidase comprises an amino acid sequence having at least 70%, preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, yet even more preferably at least 98%, especially at least 99% sequence identity to SEQ ID NO: 3.
  • Embodiment 14 Method according to any one of embodiments 1 to 13, wherein the heme peroxidase comprises the amino acid sequence as set forth in SEQ ID NO: 3.
  • Embodiment 15 Method according to any one of embodiments 1 to 14, wherein the heme peroxidase consists of the amino acid sequence as set forth in SEQ ID NO: 4.
  • Embodiment 16 Method according to any one of embodiments 1 to 15, wherein the heme cofactor is hemin.
  • Embodiment 17 Method according to any one of embodiments 1 to 16, wherein the heme peroxidase in the form of IBs is provided by the steps of:
  • Embodiment 18 Method according to embodiment 17, wherein the host cells are prokaryotic cells, preferably Escherichia coli cells.
  • Embodiment 19 Method according to embodiment 17 or 18, wherein the host cells are cultured in a volume of at least 2 L, preferably at least 5 L, more preferably at least 20 L, even 50 L, especially at least 100 L.
  • Embodiment 20 Method according to any one of embodiments 1 to 19, wherein said solubilizing comprises incubating the IBs in a solubilization buffer.
  • Embodiment 21 Method according to embodiment 20, wherein the solubilization buffer has a pH of at least 8, preferably at least 8.5, more preferably at least 9.0, even more preferably at least 9.5.
  • Embodiment 22 Method according to embodiment 20 or 21, wherein the solubilization buffer has a pH between 8 and 12.5, preferably between 8.5 and 11.5, more preferably between 9 and 11, even more preferably between 9.5 and 10.5.
  • Embodiment 23 Method according to any one of embodiments 20 to 22, wherein the solubilization buffer contains a reducing agent.
  • Embodiment 24 Method according to any one of embodiments 20 to 23, wherein the solubilization buffer has redox conditions corresponding to a dithiothreitol (DTT) concentration between 1 and 50 mmol/L, preferably between 2 and 25 mmol/L, more preferably between 4 and 15 mmol/L, especially between 6 and 8 mmol/L.
  • DTT dithiothreitol
  • Embodiment 25 Method according to any one of embodiments 20 to 24, wherein the solubilization buffer contains urea, preferably in a concentration of at least 4 mol/L, more preferably at least 5 mol/L, even more preferably at least 6 mol/L.
  • Embodiment 26 Method according to any one of embodiments 20 to 25, wherein the solubilization buffer contains between 4 mol/L and 8 mol/L urea, preferably between 5 mol/L and 7 mol/L, especially between 5.5 and 6.5 mol/L.
  • Embodiment 27 Method according to any one of embodiments 20 to 26, wherein the IBs are incubated in said solubilization buffer for at least 5 minutes, preferably at least 10 minutes, more preferably at least 15 minutes, especially at least 30 minutes.
  • Embodiment 28 Method according to any one of embodiments 20 to 27, wherein the IBs are incubated in said solubilization buffer at a temperature between 4° C. and 40° C., preferably between 10° C. and 35° C., even more preferably between 20° C. and 25° C.
  • Embodiment 29 Method according to any one of embodiments 1 to 28, wherein the solubilized IBs are mixed with the refolding buffer in a ratio between 1:5 v/v and 1:250 (solubilized IBs: refolding buffer), preferably between 1:10 and 1:100, even more preferably between 1:20 and 1:80, especially between 1:25 and 1:60, most preferably between 1:30 and 1:50.
  • solubilized IBs are mixed with the refolding buffer in a ratio between 1:5 v/v and 1:250 (solubilized IBs: refolding buffer), preferably between 1:10 and 1:100, even more preferably between 1:20 and 1:80, especially between 1:25 and 1:60, most preferably between 1:30 and 1:50.
  • Embodiment 30 Method according to any one of embodiments 1 to 29, wherein the refolding is carried out in a volume of at least 5 L, preferably at least 10 L, more preferably at least 25 L, even more preferably at least 100 L.
  • Embodiment 31 Method according to any one of embodiments 1 to 30, wherein the refolding buffer has a pH of at least 8, preferably at least 8.5, more preferably at least 9, even more preferably at least 9.5.
  • Embodiment 32 Method according to any one of embodiments 1 to 31, wherein the refolding buffer has a pH between 8 and 12.5, preferably between 8.5 and 11.5, more preferably between 9 and 11, even more preferably between 9.5 and 10.5.
  • Embodiment 33 Method according to any one of embodiments 1 to 32, wherein the difference in the pH between the solubilization buffer and the refolding buffer is less than 2 pH increments, preferably less than 1 pH increment, more preferably less than 0.5 pH increments, even more preferably less than 0.2 pH increments, especially less than 0.1 pH increments.
  • Embodiment 34 Method according to any one of embodiments 1 to 33, wherein the refolding buffer contains an oxidizing agent.
  • Embodiment 35 Method according to any one of embodiments 1 to 34, wherein the refolding buffer has redox conditions corresponding to a glutathione disulfide (GSSG) concentration between 0.2 and 6 mM GSSG, preferably between 0.4 and 4 mM GSSG, more preferably between 0.8 and 2.5 mM GSSG, especially between 1.1 and 1.6 mM GSSG.
  • GSSG glutathione disulfide
  • Embodiment 36 Method according to any one of embodiments 1 to 35, wherein the refolding buffer contains between 0.5 and 3 mol/L urea, preferably between 1 mol/L and 2.7 mol/L, even more preferably between 1.5 mol/L and 2.4 mol/L, especially between 1.8 and 2.2 mol/L.
  • Embodiment 37 Method according to any one of embodiments 1 to 36, wherein the molar ratio between DTT and GSSG in the refolding mix is between 1:2 (DTT:GSSG) and 1:30, preferably between 1:3 and 1:20, even more preferably between 1:4 and 1:15, especially between 1:6 and 1:8.
  • Embodiment 38 Method according to any one of embodiments 1 to 37, wherein the refolding mix has a reduction potential between ⁇ 105 mV and 135 mV, preferably between ⁇ 90 mV and 105 mV, even more preferably between ⁇ 80 mV and 80 mV, yet even more preferably between ⁇ 70 mV and 60 mV, most preferably between ⁇ 60 mV and 50 mV.
  • Embodiment 39 Method according to any one of embodiments 1 to 38, further comprising the step of adding salt to the refolding mix.
  • Embodiment 40 Method according to embodiment 39, wherein salt is added to the refolding mix to an ionic strength between 0.5 and 6 mol/L, preferably between 1.5 and 5 mol/L, even more preferably between 2.5 and 4.5 mol/L, especially between 3.5 and 4.5 mol/L.
  • Embodiment 41 Method according to embodiment 39 or 40, wherein the salt is sodium chloride, preferably in a concentration between 0.5 and 6 mol/L, more preferably between 1.5 and 5.5 mol/L, even more preferably between 2.5 and 5 mol/L, especially between 3.5 and 4.5 mol/L.
  • Embodiment 42 Method according to any one of embodiments 39 to 41, wherein the salt is ammonium sulfate, preferably in a concentration between 0.25 and 1.5 mol/L, preferably between 0.5 and 1.4 mol/L, even more preferably between 0.8 and 1.2 mol/L.
  • Embodiment 43 Method according to any one of embodiments 39 to 42, wherein the salt has a salting-out strength between ammonium sulfate and sodium chloride as determined by its position in the Hofmeister series, preferably wherein the concentration of the salt is between 1.25 and 6 mol/L, more preferably between 0.5 and 5 mol/L, even more preferably between 1.0 and 4.5 mol/L, most preferably between 1.5 and 4 mol/L.
  • Embodiment 44 Method according to any one of embodiments 39 to 43, wherein the salt has a weaker salting-out strength than sodium chloride as determined by its position in the Hofmeister series, preferably wherein the concentration of the salt is at least 2 mol/L, preferably at least 4 mol/L, more preferably at least 4.5 mol/L.
  • Embodiment 45 Method according to embodiment 44, wherein the concentration of the salt is between 2 mol/L and 12 mol/L, preferably between 4 mol/L and 10 mol/L, even more preferably between 4.5 mol/L and 8 mol/L.
  • Embodiment 46 Method according to any one of embodiments 1 to 45, further comprising a centrifugation step for removing impurities from the refolded heme peroxidase.
  • Embodiment 47 Method according to any one of embodiments 1 to 46, further comprising a filtration step for removing impurities from the refolded heme peroxidase.
  • Embodiment 48 Method according to any one of embodiments 1 to 47, further comprising the step of purifying the refolded heme peroxidase.
  • Embodiment 49 Method according to embodiment 48, wherein the heme peroxidase is purified after the heme cofactor has been added to the refolding mix.
  • Embodiment 50 Method according to embodiment 48 or 49, wherein the heme peroxidase is purified by chromatography.
  • Embodiment 51 Method according to any one of embodiments 48 to 50, wherein the heme peroxidase is purified by hydrophobic interaction chromatography (HIC).
  • HIC hydrophobic interaction chromatography
  • Embodiment 52 Method according to embodiment 51, wherein the stationary phase is a butyl sepharose resin.
  • Embodiment 53 Method for producing a heme peroxidase product comprising producing a heme peroxidase according to the method of any one of embodiments 1-52.
  • Embodiment 54 Method according to embodiment 53, further comprising the step of activating the heme peroxidase for a conjugation reaction.
  • Embodiment 55 Method according to embodiment 53 or 54, further comprising a conjugation reaction to obtain a heme peroxidase conjugate.
  • Embodiment 56 Method according to embodiment 55, wherein the heme peroxidase is conjugated to a binding agent, preferably an antibody.
  • Embodiment 57 Method according to embodiment 55, wherein the heme peroxidase is conjugated to an antibody fragment, preferably a single-chain variable fragment (scFv) or an antigen-binding fragment (Fab).
  • an antibody fragment preferably a single-chain variable fragment (scFv) or an antigen-binding fragment (Fab).
  • Embodiment 58 Method according to embodiment 55, wherein the heme peroxidase is conjugated to an antibody mimetic, preferably selected from the group consisting of adnectins, affibodies, anticalins, DARPins, engineered Kunitz-type inhibitors, and monobodies.
  • an antibody mimetic preferably selected from the group consisting of adnectins, affibodies, anticalins, DARPins, engineered Kunitz-type inhibitors, and monobodies.
  • Embodiment 59 Method according to embodiment 55, wherein the heme peroxidase is conjugated to an antibody binding protein, preferably protein A, protein G, or protein L.
  • an antibody binding protein preferably protein A, protein G, or protein L.
  • Embodiment 60 Method according to embodiment 55, wherein the heme peroxidase is conjugated to a further protein, preferably streptavidin.
  • Embodiment 61 Method according to any one of embodiments 53 to 60, further comprising the step of purifying the heme peroxidase or the heme peroxidase conjugate.
  • Embodiment 62 Method according to any one of embodiments 53 to 61, further comprising the step of freezing the heme peroxidase or the heme peroxidase conjugate.
  • Embodiment 63 Method according to any one of embodiments 53 to 62, further comprising the step of lyophilizing the heme peroxidase or the heme peroxidase conjugate.
  • Embodiment 64 Method according to any one of embodiments 53 to 63, further comprising the step of immobilizing the heme peroxidase or heme peroxidase conjugate on a solid carrier.
  • Embodiment 65 Method according to embodiment 64, wherein the solid carrier is a nanoparticle, preferably a magnetic nanoparticle or a nanofiber.
  • Embodiment 66 Method according to embodiment 64, wherein the solid carrier is a carbon/polyvinyl material.
  • Embodiment 67 Method according to embodiment 64, wherein the solid carrier is a membrane.
  • Embodiment 68 Method according to any one of embodiments 53 to 67, further comprising the step of packaging the heme peroxidase or the heme peroxidase conjugate in a kit.
  • Embodiment 69 Method according to embodiment 68, wherein further components selected from buffers, reagents, instructions manuals are added to the kit.
  • Embodiment 70 Method according to embodiment 69, wherein an enzyme that produces H 2 O 2 is added to the kit.
  • FIG. 1 (A) Influence of different heme cofactor concentrations and times of addition to the refolding mix on the volumetric activity, respectively the refolding yield. (B) Response contour plot for different times of heme cofactor addition and heme cofactor concentration as factors and volumetric activity [U/mL] as response (DoE 4).
  • FIG. 2 Response contour plot for the volumetric activity [U/mL] dependent on the DTT concentration in the solubilization mix and the GSSG concentration in the refolding buffer (DoE 1).
  • FIG. 3 Response contour plot for pH 8.5, pH 9.25 and pH 10 for different DTT and GSSG concentrations (both in mM) for DoE 3.
  • FIG. 4 Redox potential and volumetric activity (at-line sampling) for reactor experiment 2. 20 ⁇ M hemin was added 20 h after refolding start, at which point the redox signal shows a sharp rise.
  • FIG. 5 Redox potential and volumetric activity for reactor experiment 5. Before the end of the hemin feed, samples were drawn every 2 h and incubated with a final hemin concentration of 20 PM before measurement (full circles). After the start of the hemin feed, samples were drawn every 2 h and volumetric activity was measured immediately (full squares).
  • FIG. 6 Elution of active HRP and impurities for HIC 1 using a step gradient. Active HRP elutes between 120 and 125 mL (75% buffer B), while hydrophobic impurities elute starting from 131 mL (100% buffer B).
  • FIG. 7 Elution of active HRP and impurities for HIC 2 using a linear gradient. Active HRP elutes from 125 mL to 135 mL while hydrophobic impurities elute starting from 145 mL.
  • FIG. 8 Elution of active HRP and impurities for HIC 3 using a linear gradient. Active HRP elutes late in the gradient (around 90% buffer B), leading to an overlap with the elution of hydrophobic impurities, which elute at 100% buffer B.
  • FIG. 9 Elution of active HRP and impurities for HIC 4 using a step gradient. While separation of active HRP from hydrophobic impurities is possible using 90% buffer B, this leads to a strong tailing of the active HRP peak, resulting in a decision between lower concentration and poorer recovery of active HRP.
  • FIG. 10 Elution of active HRP and impurities for HIC 5 using a step gradient. Active HRP elutes between 1250 and 1400 mL (75% buffer B), while hydrophobic impurities elute starting from 1400 mL (100% buffer B).
  • FIG. 11 Chromatogram of the HIC run with refolding at pH 8.5. Pure HRP elutes at 75% buffer B, whereas hydrophobic impurities elute at 100% buffer B.
  • FIG. 12 Chromatogram of the HIC run with refolding at pH 10. Pure HRP elutes at 75% buffer B, whereas hydrophobic impurities elute at 100% buffer B.
  • FIG. 13 Residual activities of HRP N13D/N57S/P146Q/N175S/N255D/N268D/N275K (mHRP, SEQ ID NO: 4) compared to recombinant wild-type HRP (rHRP, SEQ ID NO: 2) and plant-derived HRP (pHRP).
  • mHRP wild-type HRP
  • pHRP plant-derived HRP
  • 150 ⁇ l of pHRP (triangles), mHRP (squares) and rHRP (circles) with a concentration of 2.9 ⁇ M were incubated in 50 mM BisTris/HCl pH 7, 0.5 M NaCl, 7% glycerol for up to 10 h at 60° C.
  • FIG. 14 Enzyme activities obtained from three different refolding experiments. “Batch addition”: heme cofactor was added in batch after 20 h refolding time (first column). “Hemin feed 10 h”: heme cofactor was added 8 h after refolding start as a 10-hour feed (second column). “Hemin feed 1 h”: heme cofactor was added 8 h after refolding start as a 1-hour feed; measurements were taken directly after the end of the feed (last column) as well as after further incubation for 10 h (third column).
  • GSSG L-Gluthathione oxidized
  • ABTS 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
  • Hemin was purchased from Sigma (Hemin from bovine, ⁇ 90%).
  • Dithiothreitol (DTT) and all other chemicals were purchased from Roth.
  • the hrp gene coding for HRP variant C1A was codon-optimized for E. coli and obtained from GenScript USA Inc. (Piscataway, NJ, USA).
  • the plasmid pET21d+ was used for HRP inclusion body production in the cytoplasm. A stop codon was introduced so that the protein is produced without any tags.
  • HRP was produced in E. coli BL21(DE3) in a 10 L Biostat Cplus stainless steel bioreactor (Satorius, Germany). HRP production was induced with 0.5 mM isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) in a fed-batch cultivation for 12 h using DeLisa medium. Biomass was harvested by centrifugation and the wet biomass was stored at ⁇ 20° C. until further processing.
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • Biomass was resuspended using an IKA T10 basic ULTRA-TURRAX in 3-5 mL buffer A/g wet biomass (Buffer A: 50 mM TRIS/HCl; pH 8; 500 mM NaCl; 1.5 mM EDTA) and homogenized (using a GEA Niro Soavi Panda PLUS) (>1300 bar, 3 passages, cooled).
  • Buffer A 50 mM TRIS/HCl; pH 8; 500 mM NaCl; 1.5 mM EDTA
  • homogenized using a GEA Niro Soavi Panda PLUS
  • the homogenized suspension was centrifuged (15650 g; 20 min, 4° C.), the supernatant discarded and the cell debris resuspended in 10 mL buffer B/g wet cell debris (Buffer B: 50 mM TRIS/HCl; pH 8; 500 mM NaCl; 2 M Urea) and centrifuged again (15650 g; 20 min, 4° C.). The washing step using buffer B was repeated once. Afterwards, IBs/cell debris were resuspended in water (5 mL water/g wet cell debris), the suspension aliquoted into pre-weighed 50 mL reaction tubes, centrifuged (15650 g; 20 min, 4° C.) and the pellets stored at ⁇ 20° C. until further use.
  • Buffer B 50 mM TRIS/HCl; pH 8; 500 mM NaCl; 2 M Urea
  • solubilization buffer 1 50 mM TRIS/HCl; pH 8; 6 M Urea/Solubilization buffer 2: 50 mM Glycine; pH 10; 6 M Urea
  • DTT was added (using a 1 M DTT stock) to reach a final concentration in the solubilization mix varying from 1 mM-28.44 mM DTT and the solubilization mix was incubated (RT; 0.5 h; slight agitation), followed by centrifugation (20379 g; 20 min; 4° C.). The supernatant was immediately used for refolding, the pellet discarded.
  • HRP enzyme activity was measured with a Tecan Infinite M200 PRO using flat-bottom polystyrene 96 well plates. Depending on concentration of correctly folded HRP, samples were diluted 1:50-1:200 in dilution buffer (Dilution buffer: 20 mM Bis-Tris pH 7; 7% v/v Glycerol). 170 ⁇ L of ABTS solution (5 mM ABTS in 50 mM KH 2 PO 4 pH 5) were mixed with 10 ⁇ L of diluted sample in the well, after which 20 ⁇ L of H 2 O 2 (10 mM H 2 O 2 ) were added to start the reaction. Immediately afterwards, the change of absorption at 420 nm over 2 minutes was recorded (at 30° C.). The volumetric enzyme activity was calculated using the following formula:
  • a [ U / mL ] V t ⁇ o ⁇ t ⁇ a ⁇ l * ⁇ ⁇ A / min * dilution V s ⁇ a ⁇ m ⁇ p ⁇ l ⁇ e * d * ⁇ ,
  • SEC-HPLC Purity of the active HRP fraction after the capture step with HIC was measured using a SEC-HPLC. For this, an XBridge Protein BEH SEC Column, 200 ⁇ , 3.5 ⁇ m, 7.8 mm ⁇ 150 mm (Waters) was used. The method was run at 0.5 mL/min with 100% Buffer A (Buffer A: 80 mM Phosphate pH 6.8; 250 mM KCl) for 18 minutes. The column was kept at a constant temperature of 25° C. and 214 nm, 280 nm and 404 nm were measured.
  • Buffer A Buffer A: 80 mM Phosphate pH 6.8; 250 mM KCl
  • Rösiere Rissersress was measured as the ratio of absorbance at 404 nm to 280 nm. Absorbance measurement was done using a Hitachi Double Beam Spectrophotometer U-2900.
  • MODDE 10 Planning and analysis of Design of Experiments (DoE) were done using Umetrics MODDE 10.
  • DoE1 For the first DoE (Design of experiments), the DTT concentration for solubilization (solubilization buffer 1; pH 8) and the GSSG concentration in the refolding buffer (refolding buffer 1; pH 8.5) were varied (see Table 1), while the hemin addition was kept constant at 20 ⁇ M after 20 h. A CCF (central composite face-centered design) with the volumetric activity after refolding as a response was used.
  • DoE2 For the second DoE, the DTT concentration for solubilization (solubilization buffer 1; pH 8), the GSSG concentration in the refolding buffer (refolding buffer 1; pH 8.5) and the protein concentration in the refolding mix were varied (see Table 2), while the hemin addition was kept constant at 20 ⁇ M after 20 h. A CCF (central composite face-centered design) with the volumetric and specific activity after refolding as a response was used.
  • DoE3 For the third DoE, the DTT concentration for solubilization, the GSSG concentration in the refolding buffer and the pH of the solubilization and refolding buffer were varied (see Table 3). For pH 8.5 solubilization and refolding buffer 1 was used, for pH 10 solubilization and refolding buffer 2 was used. The hemin addition was kept constant at 20 ⁇ M after 20 h. A CCF (central composite face-centered design) with the volumetric Activity after refolding as a response was used.
  • DoE4 For this DoE, time and concentration of hemin addition were varied between 0 h-24 h after refolding start and 6 ⁇ M-80 ⁇ M Hemin, respectively. The exact factors used are shown in Table 4. Solubilization buffer 1 (pH 8) and refolding buffer 1 (pH 8.5) was used for all experiments. The volumetric activity was used as the response in order to optimize both factors.
  • a Design of Experiment using DTT and GSSG concentration was performed (DoE1) in order to obtain the optimal redox system during solubilization and refolding.
  • DoE1 Design of Experiment using DTT and GSSG concentration
  • This approach has the advantage that it spans the two unit operations solubilization and refolding and uses the refolding yield (volumetric activity) as a response. Thereby, the final yield of the process is maximized instead of using a response as e.g. the solubilization yield to optimize the single unit operations.
  • DoE1 Design of Experiment using DTT and GSSG concentration
  • FIG. 3 shows the 4D contour plot for the final model with the volumetric activity as a response. For pH 10, the maximal yield is achieved for 6.7 mM DTT and 1.26 mM GSSG.
  • Example 2 General materials and methods were as described in Example 1 unless specified otherwise. Analytical methods were used as described in Example 2.
  • Reactor experiment 1 For this experiment, the solubilization mix contained 1 mM DTT and the refolding buffer contained 0.35 mM GSSG. Solubilization buffer 1 (pH 8) and refolding buffer 1 (pH 8.5) was used. Hemin was added 20 h after refolding start to a final concentration of 20 ⁇ M.
  • Reactor experiment 2 For this experiment, the solubilization mix contained 7.11 mM DTT and the refolding buffer contained 1.27 mM GSSG. Solubilization buffer 1 (pH 8) and refolding buffer 1 (pH 8.5) was used. Hemin was added 20 h after refolding start to a final concentration of 20 ⁇ M. Samples (2 mL in reaction tubes) were taken every 2 h, hemin was added to reach a final concentration of 20 ⁇ M (only for samples taken before hemin addition; the samples taken after hemin addition already contained 20 ⁇ M), incubated (2 h; 4° C., slight agitation) and then enzyme activity was measured.
  • Reactor experiment 3 For this experiment, the solubilization mix contained 1 mM DTT and the refolding buffer contained 0.35 mM GSSG. Solubilization buffer 2 (pH 10) and refolding buffer 2 (pH 10) was used. Hemin was added 20 h after refolding start to a final concentration of 20 ⁇ M.
  • Reactor experiment 4 For this experiment, the solubilization mix contained 7.11 mM DTT and the refolding buffer contained 1.27 mM GSSG. Solubilization buffer 2 (pH 10) and refolding buffer 2 (pH 10) was used. Hemin was added 20 h after refolding start to a final concentration of 20 ⁇ M.
  • Reactor experiment 5 For this experiment, the solubilization mix contained 7.11 mM DTT and the refolding buffer contained 1.27 mM GSSG. Solubilization buffer 1 (pH 8) and refolding buffer 1 (pH 8.5) was used. A constant feed (2 mL 1 mM Hemin/h; final concentration 20 ⁇ M Hemin) was applied from 8 h after refolding start until 20 h (12 h feed time). As for reactor 2, samples were drawn every 2 h and activity was measured.
  • Example 2 Based on small scale optimization (Example 2) a hemin addition 20 h after refolding start to a final concentration of 20 ⁇ M was used for reactor experiment 2. Before the addition of hemin (i.e. for the first 20 hours), samples were taken every 2 h to measure the activity at-line ( FIG. 4 ). In order to measure the volumetric activity, which correlates to the refolding success, 20 ⁇ M hemin were added to each sample immediately after sampling and the activity was measured after incubation for two hours. After the addition of hemin to the reactor (i.e. after 20 hours), samples were still taken every 2 h but no further hemin was added. Still, the samples were incubated under the same conditions (2 hours before measurement) as before.
  • a linear hemin feed was applied 8 h after the start of refolding for a total feed duration of 12 h.
  • Samples were drawn according to the sampling procedure described for reactor experiment 2 (every two hours). After the start of the hemin feed, samples were measured both once without further addition of hemin (i.e. with a low hemin concentration at the start of the hemin feed; samples b1-b10 in Table 6), and once after the addition of hemin to reach a final concentration of 20 ⁇ M hemin and incubation for further 2 h (sa1-a9 in Table 6).
  • FIG. 5 shows the redox potential as well as the measured volumetric activities. Compared to reactor experiment 2 ( FIG. 4 ), the beginning of the refolding is very similar for both experiments, with the volumetric activity achieved after 8 h being 32.0 for experiment 2 and 33.1 for experiment 5. However, the linear hemin feed applied for experiment 5 leads to a 25% increase in refolding yield compared to experiment 2 after the addition of hemin.
  • Example 2 In order to confirm the results obtained using small scale experiments (Example 2), four reactor experiments were performed. The conditions as well as the final specific activity are listed in Table 7. In general, these are in good concordance with the results obtained using the small-scale experiments, with the optimized DTT/GSSG concentration at pH 10 showing the highest refolding yield.
  • hydrophobic interaction chromatography HIC was used as a capture step after the refolding.
  • HIC hydrophobic interaction chromatography
  • This has the advantage that binding conditions require high salt concentrations, which precipitate impurities such as excess hemin, aggregates and impurities, while correctly folded HRP is stable up to a high salt concentration.
  • This has the advantage that these impurities are separated from the load used for the capture step, resulting in a higher binding capacity and easier cleaning and regeneration of the chromatographic resin.
  • the load was prepared as described above by adding 267 g NaCl/1 L refolding mix.
  • the column was equilibrated with Buffer A (Buffer A: 20 mM Bis-Tris pH 7; 7% Glycerol; 4 M NaCl) and 49 mL load were applied after all signals were constant during equilibration. After the load, a washing step with buffer A (8 mL; 8 CVs) was performed.
  • Buffer B 20 mM Bis-Tris pH 7; 7% Glycerol/8 mL; 8 CVs
  • 75% Buffer B 10 mL; 10 CVs
  • 100% (17 mL; 17 CVs) Buffer B with active HRP eluting at 75% Buffer B.
  • Volumetric enzyme activity [U/mL] and protein concentration were measured for all fractions. The purity of the active pool was determined using SEC-HPLC and the Rillonsiere.
  • This capture step presents the optimized method for the purification and capture of HRP after refolding.
  • FIG. 6 shows the step elution used for this experiment and Table 12 the corresponding analytics. Active HRP is concentrated around 9 fold for the chromatography step, resulting in 0.5 g/L, which is expected to further improve during scale up. More hydrophobic impurities elute at 100% buffer B, leading to a good resolution for this method. The ratio of the 404 nm signal to the 280 nm signal suggests a high purity for the active fraction. This was further confirmed by SEC-HPLC (purity ⁇ 98%). Therefore, this presents a way to obtain pure, correctly folded and fully active HRP produced from E. coli inclusion bodies.
  • the load was prepared as described above by adding 132 g (NH 4 ) 2 SO 4 /1 L refolding mix.
  • a HiTrap Octyl FF 1 mL (GE Healthcare) was used with a flow rate of 1 mL/min (150 cm/h; 1 CV/min).
  • the column was equilibrated with Buffer A (Buffer A: 20 mM Tris pH 8.5; 7% Glycerol; 1 M (NH 4 ) 2 SO 4 ) and 50 mL load were applied after all signals were constant during equilibration. After the load, a wash step with buffer A (16 mL; 16 CVs) was performed.
  • HIC experiment 4 the load was prepared as described above by adding 267 g NaCl/1 L refolding mix.
  • a HiTrap Phenyl FF (High Sub) 1 mL (GE Healthcare) was used with a flow rate of 0.5 mL/min (75 cm/h; 0.5 CV/min).
  • the column was equilibrated with Buffer A (Buffer A: 20 mM Tris pH 8.5; 7% Glycerol; 4 M NaCl) and 50 mL load were applied after all signals were constant during equilibration. After the load, a wash step with buffer A (10 mL; 10 CVs) was performed.
  • FIG. 10 shows the elution of the active HRP fraction as well as the impurities. Active HRP was concentrated to a final concentration of 0.95 g/L and a volumetric activity of 1500 U/mL with a Rechsress comparable to that of plant HRP (2.72). These results confirmed the expectation that scale-up from 1 mL column volume leads to a higher concentration, as discussed for HIC 1.
  • Protein concentration was determined using the method according to Bradford (Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry, 1976. 72(1-2): p. 248-254). 200 ⁇ l Bradford solution were mixed with 5 ⁇ l sample and the change in absorbance at 595 nm was measured with a Tecan Infinite M200 PRO instrument over the course of 10 min.
  • TFA trifluoroacetic acid
  • Size exclusion HPLC Purity of the active HRP fraction after the capture step with HIC was measured using a SEC-HPLC. For this, a BEH 200A SEC 1.7 ⁇ m 4.6 ⁇ 300 mm, 3.5 ⁇ m (Waters) column was used. The method was run at 0.3 mL/min with 100% Buffer A (Buffer A: 80 mM Phosphate pH 6.8; 250 mM KCl) for 18 minutes. The column was kept at a constant temperature of 30° C. and 214 nm, 280 nm and 404 nm were measured.
  • Buffer A Buffer A: 80 mM Phosphate pH 6.8; 250 mM KCl
  • Example 3 Strains and growth conditions as well as homogenization and inclusion body wash were performed as described in Example 1. A refolding reactor was used as described in Example 3.
  • solubilization buffer 1 50 mM TRIS/HCl; pH 8.5; 6 M Urea/Solubilization buffer 2: 50 mM glycine; pH 10; 6 M Urea
  • solubilization buffer 1 50 mM TRIS/HCl; pH 8.5; 6 M Urea/Solubilization buffer 2: 50 mM glycine; pH 10; 6 M Urea
  • DTT was added (using a 1 M DTT stock) to reach a final concentration in the solubilization mix of 7.11 mM DTT and the solubilization mix was incubated (4° C.; 0.5 h; slight agitation), followed by centrifugation (20379 g; 20 min; 4° C.). The supernatant was immediately used for refolding, the pellet discarded.
  • Reactor runs were carried out at pH 8.5 and at pH 10, as follows.
  • refolding volume for the vessel was 1.2 L (resulting in the use of 30 mL solubilizate and a dilution of 1:40).
  • the refolding buffer contained 20 mM TRIS/HCl pH 8.5, 2 M urea, 7% glycerol, 2 mM CaCl 2 , 1.27 mM GSSG.
  • a constant feed (2.4 mL 1 mM Hemin/h; final concentration 20 ⁇ M Hemin) was applied from 8 h after refolding start until 18 h (10 h feed time) and the reactor run was terminated after 19 h.
  • 0.27 g NaCl/ml refolding mix were added over the course of 30 min while stirring at room temperature.
  • final refolding volume for the vessel was 1.2 L (resulting in the use of 30 mL solubilizate and a dilution of 1:40).
  • the refolding buffer contained 20 mM glycine pH 10 (adjusted with HCl), 2 M urea, 7% glycerol, 2 mM CaCl 2 , 1.27 mM GSSG.
  • a constant feed (2.4 mL 1 mM Hemin/h; final concentration 20 ⁇ M Hemin) was applied from 8 h after refolding start until 18 h (10 h feed time) and the reactor run was terminated after 19 h. Before salt precipitation the pH was lowered from pH 10 to pH 8.5 with HCl.
  • HIC HIC
  • Buffer A Buffer A: 20 mM BisTris pH 7; 4 M NaCl
  • 1250-1300 mL load were applied at a flow rate of 90 cm/h.
  • a wash step with 20% buffer B Buffer B: 20 mM Bis-Tris pH 7 was performed at a flow rate of 90 cm/h for 2 CVs.
  • Plant HRP Type VI-A (Cat. No.: P6782) was obtained from Sigma-Aldrich (St. Louis, MO, USA). All HRP variants produced in E. coli consisted of the sequence as set forth in SEQ ID NO: 2 with the indicated mutations unless specified otherwise.
  • HRP variant C1A wild-type HRP; SEQ ID NO: 2
  • GenSript USA Inc. GenSript USA Inc.
  • HRP was produced from pSF-T7-LacO-NH2-dsbA (OG4591) (Oxford Genetics Ltd., Oxford, UK) or pET21d+ (Novagen, San Diego, CA, USA) in the E.
  • the plasmid pSFT7 encodes a Dsb tag for export into the periplasm which is cleaved off after translocation.
  • the plasmid pET21d+ was used for HRP inclusion body production in the cytoplasm. A stop codon was introduced so that the protein is produced without any tags.
  • SB medium 32 g L ⁇ 1 tryptone; 20 g L ⁇ 1 yeast extract; 5 g L ⁇ 1 NaCl; 5 mM NaOH
  • BL21 DE3 cells that comprised vector pET21d+ with the hrp gene (or variants thereof) devoid of any N- or C-terminal tags.
  • Ampicillin was added to a final concentration of 100 mg L ⁇ 1 .
  • Pre-cultures were grown overnight at 37° C. with shaking (250 rpm) in 50 mL SB Amp medium and 2.5 L Ultra Yield Flasks (UYF) were inoculated to reach an optical density (OD 600 ) of 0.3 in a final volume of 500 mL SB Amp medium.
  • the cells were grown at 37° C. with shaking (250 rpm) until an OD 600 of 0.5, subsequently hrp expression was induced by adding 0.1 mM isopropyl ⁇ -D-1-thiogalactopyranoside (IPTG). After growth for 20 h at 25° C. and 250 rpm, the cells were harvested by centrifugation (5000 g, 20 min, 4° C.).
  • IPTG isopropyl ⁇ -D-1-thiogalactopyranoside
  • Biomass was resuspended using an IKA T10 basic ULTRA-TURRAX in 3-5 mL buffer A/g wet biomass (Buffer A: 50 mM TRIS/HCl; pH 8; 500 mM NaCl; 1.5 mM EDTA) and homogenized (using a GEA Niro Soavi Panda PLUS) (>1300 bar, 3 passages, cooled).
  • Buffer A 50 mM TRIS/HCl; pH 8; 500 mM NaCl; 1.5 mM EDTA
  • homogenized using a GEA Niro Soavi Panda PLUS
  • the homogenized suspension was centrifuged (15650 g; 20 min, 4° C.), the supernatant discarded and the cell debris resuspended in 10 mL buffer B/g wet cell debris (Buffer B: 50 mM TRIS/HCl; pH 8; 500 mM NaCl; 2 M Urea) and centrifuged again (15650 g; 20 min, 4° C.). The washing step using buffer B was repeated once. Afterwards, IBs/cell debris were resuspended in water (5 mL water/g wet cell debris), the suspension aliquoted into pre-weighed 50 mL reaction tubes, centrifuged (15650 g; 20 min, 4° C.) and the pellets stored at ⁇ 20° C. until further use.
  • Buffer B 50 mM TRIS/HCl; pH 8; 500 mM NaCl; 2 M Urea
  • solubilization an aliquot of the frozen IBs was thawed, weighed in order to calculate the wet Inclusion Body (wIB) weight and resuspended in the appropriate solubilization buffer (50 mM TRIS/HCl; pH 8.5; 6 M Urea) to reach a wIB concentration of 100 g/L.
  • solubilization buffer 50 mM TRIS/HCl; pH 8.5; 6 M Urea
  • DTT was added (using a 1 M DTT stock) to reach a final concentration in the solubilization mix of 7.11 mM DTT and the solubilization mix was incubated (4° C.; 0.5 h; slight agitation), followed by centrifugation (20379 g; 20 min; 4° C.). The supernatant was immediately used for refolding, the pellet discarded.
  • the solubilizate was diluted 1:40 in the appropriate refolding buffer (e.g. 20 mM TRIS/HCl pH 8.5, 2 M urea, 7% glycerol, 2 mM CaCl 2 , 1.27 mM GSSG), to which hemin was added in a final concentration of 20 ⁇ M and refolding was carried out at 10° C. for 19 hours.
  • the appropriate refolding buffer e.g. 20 mM TRIS/HCl pH 8.5, 2 M urea, 7% glycerol, 2 mM CaCl 2 , 1.27 mM GSSG
  • the proteins were further purified by hydrophobic interaction chromatography (HIC).
  • HIC hydrophobic interaction chromatography
  • the column was equilibrated with Buffer A (Buffer A: 20 mM BisTris pH 7; 4 M NaCl) at a flow rate of 113 cm/h until all signals were constant. Then 1250-1300 mL load were applied at a flow rate of 90 cm/h.
  • a wash step with 20% buffer B Buffer B: 20 mM Bis-Tris pH 7
  • a step elution was performed with 75% buffer B (79 cm/h) and 100% (90 cm/h) buffer B, with active HRP eluting at 75% buffer B.
  • Enzyme kinetic parameters were determined for the substrates ABTS, TMB and hydrogen peroxide in a 96-well plate assay using a Tecan Infinite M200 PRO instrument (Tecan, Switzerland).
  • the reaction mixture in each well of the 96-well plate contained a saturating hydrogen peroxide concentration of 1 mM and varying TMB concentrations (20-550 ⁇ M) in 50 mM phosphate-citrate buffer pH 5 in a final volume of 200 ⁇ L.
  • Protein sample (5 ⁇ L) was mixed with 175 ⁇ l TMB-buffer mixture and the reaction was started with 20 ⁇ l hydrogen peroxide solution (10 mM). The increase in absorption was followed at 652 nm for 60s at 30° C. in a Tecan Infinite M200 PRO instrument.
  • the reaction mixture in each well of the 96-well plate contained a saturating hydrogen peroxide concentration of 1 mM and varying ABTS concentrations (0.1-7 mM) in 50 mM phosphate-citrate buffer pH 5 in a final volume of 200 ⁇ L.
  • Protein sample (5 ⁇ L) was mixed with 175 ⁇ l ABTS-buffer mixture and the reaction was started with 20 ⁇ l hydrogen peroxide solution (10 mM). The increase in absorption was followed at 420 nm for 120 s at 30° C. in a Tecan Infinite M200 PRO instrument.
  • the reaction mixture in each well of the 96-well plate contained a saturating ABTS of 10 mM and varying hydrogen peroxide concentrations (0.001-1 mM) in 50 mM phosphate-citrate buffer pH 5 in a final volume of 200 ⁇ L.
  • Protein sample (5 ⁇ L) was mixed with 145 ⁇ l hydrogen peroxide-buffer mixture and the reaction was started with 50 ⁇ l ABTS solution (40 mM). The increase in absorption was followed at 420 nm for 120 s at 30° C. in a Tecan Infinite M200 PRO instrument.
  • the thermal stability of the enzyme variants was assessed at 60° C. in 50 mM BisTris/HCl pH 7, 7% glycerol, 500 mM NaCl.
  • the enzymatic activity with ABTS was measured after 0, 30, 60, 90 and 120 min for HRP wild-type (SEQ ID NO: 2) and HRP N13D/N57S/N255D/N268D; after 0, 90, 180, 300, 420 and 588 min for variants HRP N13D/N57S/N175S/N255D/N268D, HRP N13D/N57S/P146Q/N175S/N255D/N268D, HRP N13D/N57S/N175S/N255D/N268D/N275K and HRP N13D/N57S/P146Q/N175S/N255D/N268D/N275K and after 0, 90, 180, 300 and 420 min for plant HRP.
  • the enzyme concentration of all variants including plant HRP was 2.86 ⁇ M during the heat treatment. Afterwards the samples were cooled on ice for 5 min before centrifugation at 16162 g for 15 min at 4° C. Subsequently the residual activity was measured with 7 mM ABTS with a Tecan Infinite M200 PRO instrument.
  • the reaction mixture contained 5 ⁇ L of protein, a saturating hydrogen peroxide concentration of 1 mM and 7 mM ABTS in 50 mM phosphate-citrate buffer pH 5 with a total volume of 200 ⁇ l. The increase in absorption was followed at 420 nm for 120 s at 30° C.
  • HRP N13D/N57S/P146Q/N175S/N255D/N268D/N275K (SEQ ID NO: 4) was found to be significantly more active than HRP N13D/N57S/N175S/N255D/N268D with the substrates TMB and hydrogen peroxide.
  • the mutations P146Q and N275K were found to have a strong beneficial effect on enzymatic activity.
  • plasmids were constructed with standard molecular cloning techniques.
  • Whole plasmid PCR of HRP N13D/N57S/P146Q/N175S/N255D/N268D/N275K (SEQ ID NO: 3) in pSF-T7 was used to introduce mutations in the hrp gene by site-saturation mutagenesis at position 146 and 275.
  • the 6.3 kb fragment was amplified with the respective oligonucleotides to generate site-saturation libraries (Table 21). All oligonucleotides were purchased from Microsynth (Balgach, Switzerland).
  • the oligonucleotides were phosphorylated according to following protocol: 300 ⁇ mol primer DNA, 1 ⁇ T4 PNK buffer (NEB), 1 mM ATP, 5% PEG, 10 Units T4 polynucleotide kinase (PNK, NEB). The reaction was incubated at 37° C. for 45 min prior to heat inactivation at 65° C. for 20 min. Each PCR reaction contained 1 ⁇ Q5 Reaction Buffer, 200 ⁇ M dNTP Mix, 200 nM of both forward and reverse phosphorylated primer, 100 ng template vector DNA and 1 U Q5 High-Fidelity DNA Polymerase.
  • the PCR products were purified with the Monarch PCR & DNA Cleanup Kit from New England Biolabs (NEB, Ipswich, MA, USA) and the template plasmid DNA was removed by FastDigest DpnI (Thermo ScientificTM, Waltham, MA, USA) digestion. 2 FDU (FastDigest unit) of DpnI was added to the cleaned PCR products and incubated for 4 h at 37° C. After heat inactivation at 80° C. for 20 min, the plasmids were blunt end ligated: 50 ng plasmid DNA, 1 ⁇ T4 DNA ligase buffer (NEB), 400 cohesive end units T4 DNA ligase (NEB), 16° C. overnight. After heat inactivation for 20 min at 65° C. the plasmids were transformed into BL21 (DE3).
  • Positive transformants were picked from the selection plates and grown in 96-well plates with 200 ⁇ l SB medium (32 g L ⁇ 1 tryptone; 20 g L ⁇ 1 yeast extract; 5 g L-1 NaCl; 5 mM NaOH; 50 mg L ⁇ 1 kanamycin) for 16 h at 37° C., 250 rpm in a plastic box to prevent desiccation. Subsequently, 90 ⁇ l 75% glycerol was added to the master plates before they were stored at ⁇ 80° C. The slave plates containing 190 ⁇ l SB medium were inoculated with 10 ⁇ l of the master plates.
  • SB medium 32 g L ⁇ 1 tryptone; 20 g L ⁇ 1 yeast extract; 5 g L-1 NaCl; 5 mM NaOH; 50 mg L ⁇ 1 kanamycin
  • the medium contained 2 mM CaCl 2 ; 6 ⁇ M hemin and 0.1 mM IPTG in a final volume of 200 ⁇ l.
  • the cells were grown for 16 h at 25° C., 250 rpm in a plastic box and cell density was determined by measuring the absorption at 595 nm with a Tecan Infinite M200 PRO (Tecan, Switzerland) plate reader. Then the plates were centrifuged at 5000 g for 6 min at 4° C.
  • Results of the selected mutants are given in Table 22 (position P146) and Table 23 (position N275) below. Since the present Example uses a 96-well plate-based screening assay, variability (standard deviation) is higher than with other assays reported herein. Therefore, results for each mutant should only be compared within each plate measured.
  • PLATE 1 146Q (control) 0.056 ⁇ 0.008 49% ⁇ 14% 146A 0.054 50% 146E 0.048 53% 146R 0.052 60% 146R 0.053 59% 146Q 0.057 60%
  • PLATE 2 146Q (control) 0.058 ⁇ 0.004 74% ⁇ 6% 146V 0.049 75% 146Q 0.059 77% 146Q 0.057 77% 146Q 0.056 82%
  • Example 5 Process runs were carried out as described in Example 5 with the differences indicated below. Strains and growth conditions as well as homogenization and inclusion body wash were performed as described in Example 1. A refolding reactor was used as described in Example 3.
  • solubilization buffer 2 50 mM glycine; pH 10; 6 M Urea
  • the refolding buffer contained 20 mM glycine pH 10 (adjusted with HCl), 2 M urea, 7% glycerol, 2 mM CaCl 2 ), 1.27 mM GSSG.
  • the beneficial effect of mutations at positions P146 and N275 was investigated in the light of wild-type HRP (SEQ ID NO: 2), HRP N175S and HRP N13D/N57S/N175S/N255D/N268D. Furthermore, the beneficial effects of single mutants and combinations thereof was examined. In this context, the role of mutations at positions P146 and N275 on the biochemical properties was determined by the measurement of specific enzyme activity and thermal stability at 60° C.
  • ABSTS Specific Enzyme Activity
  • HRP P146Q showed a 1.4-fold higher specific activity in relation to HRP wild-type.
  • HRP N175S showed a lower specific activity; however, HRP N13D/N57S/P146Q/N175S/N255D/N268D/N275K (SEQ ID NO: 4) was able to counteract this activity reduction and restored it to HRP wild-type values.
  • HRP variants [U/mg] HRP wild-type (SEQ ID NO: 2) 962 ⁇ 108 HRP N13D/N57S/P146Q/N175S/N255D/N268D/ 875 ⁇ 81 N275K (SEQ ID NO: 4) HRP P146Q 1391 ⁇ 115 HRP N175S 693 ⁇ 77 HRP N275K 956 ⁇ 58 HRP P146Q/N275K 974 ⁇ 75 HRP P146Q/N175S 637 ⁇ 47 HRP N175S/N275K 601 ⁇ 94 HRP P146Q/N175S/N275K 637 ⁇ 44 Specific Enzyme Activity (H 2 O 2 )
  • the specific activity in Units/mg protein was determined with the substrate hydrogen peroxide.
  • the trend was the same as observed for the data for ABTS, where the variant P146Q led to an increase in specific activity and introduction of N175S led to lower values.
  • N175S was missing or when the additional mutations of SEQ ID NO: 4 were present, the specific activity was comparable or even better than SEQ ID NO: 2.
  • HRP variants [U/mg] HRP wild-type (SEQ ID NO: 2) 1151 ⁇ 113 HRP N13D/N57S/P146Q/N175S/N255D/N268D/ 983 ⁇ 104 N275K (SEQ ID NO: 4) HRP P146Q 1522 ⁇ 133 HRP N175S 734 ⁇ 54 HRP N275K 1258 ⁇ 90 HRP P146Q/N275K 1027 ⁇ 31 HRP P146Q/N175S 756 ⁇ 25 HRP N175S/N275K 711 ⁇ 35 HRP P146Q/N175S/N275K 718 ⁇ 28 Specific Enzyme Activity (TMB)
  • HRP variants [U/mg] HRP wild-type (SEQ ID NO: 2) 6316 ⁇ 434 HRP N13D/N57S/P146Q/N175S/N255D/N268D/ 5836 ⁇ 552 N275K (SEQ ID NO: 4) HRP P146Q 7781 ⁇ 411 HRP N175S 5312 ⁇ 152 HRP N275K 5974 ⁇ 495 HRP P146Q/N275K 5699 ⁇ 294 HRP P146Q/N175S 5329 ⁇ 122 HRP N175S/N275K 5465 ⁇ 520 HRP P146Q/N175S/N275K 5227 ⁇ 90 Thermal Stability
  • HRP N13D/N57S/P146Q/N175S/N255D/N268D and HRP N13D/N57S/N175S/N255D/N268D/N275K when compared to HRP N13D/N57S/P146Q/N175S/N255D/N268D/N275K (SEQ ID NO: 4).
  • HRP variants [min] HRP wild-type (SEQ ID NO: 2) 30 ⁇ 3 HRP N13D/N57S/P146Q/N175S/N255D/N268D/ 378 ⁇ 11 N275K (SEQ ID NO: 4) HRP P146Q 25 ⁇ 0.5 HRP N275K 23 ⁇ 1 HRP P146Q/N275K 25 ⁇ 1 HRP P146Q/N175S 178 ⁇ 1 HRP N175S/N275K 166 ⁇ 1 HRP P146Q/N175S/N275K 236 ⁇ 1 HRP N175S 232 ⁇ 3 HRP N13D/N57S/N255D/N268D 46 ⁇ 0.5 HRP N13D/N57S/P146Q/N175S/N255D/N268D 267 ⁇
  • N175S was found to strongly increase thermal stability of HRP. This effect was observed for N175S on its own and even more strongly in combination with the mutated N-glycosylation site amino acids N13D/N57S/N255D/N268D, where a synergistic effect was observed.
  • the combination of the single mutation P146Q or the single mutation N275K with N175S led to a slight stability reduction; however, when both P146Q and N275K were combined with N175S the reduction was alleviated, suggesting a synergistic effect between P146Q, N275K, and N175S.
  • N175S was found to reduce enzyme activity with several substrates. This effect was, however, counteracted by N13D/N57S/P146Q/N175S/N255D/N268D/N275K (SEQ ID NO: 4). Thus, this mutant provides a combination of high thermal stability and optimal kinetic performance.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
US17/914,054 2020-03-24 2021-03-24 Methods for producing heme peroxidases Active 2042-06-27 US12448639B2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP20165131.2 2020-03-24
EP20165131 2020-03-24
EP20165131.2A EP3884956A1 (de) 2020-03-24 2020-03-24 Verfahren zur herstellung von hämperoxidasen
EP20167716 2020-04-02
EP20167716.8 2020-04-02
EP20167716 2020-04-02
EP20177549 2020-05-29
EP20177549 2020-05-29
EP20177549.1 2020-05-29
PCT/EP2021/057532 WO2021191253A1 (en) 2020-03-24 2021-03-24 Methods for producing heme peroxidases

Publications (2)

Publication Number Publication Date
US20230122727A1 US20230122727A1 (en) 2023-04-20
US12448639B2 true US12448639B2 (en) 2025-10-21

Family

ID=74947519

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/914,054 Active 2042-06-27 US12448639B2 (en) 2020-03-24 2021-03-24 Methods for producing heme peroxidases

Country Status (6)

Country Link
US (1) US12448639B2 (de)
EP (1) EP4125985B1 (de)
JP (1) JP7671077B2 (de)
CN (1) CN115427058A (de)
ES (1) ES3063878T3 (de)
WO (1) WO2021191253A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116930160B (zh) * 2023-05-26 2026-04-07 杭州澳麒生物科技有限公司 一种目视比色法检测细胞游离亚铁原卟啉含量的显色液及试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072999A1 (en) 2000-03-27 2001-10-04 California Institute Of Technology Expression of functional eukaryotic proteins
US6902918B1 (en) * 1998-05-21 2005-06-07 California Institute Of Technology Oxygenase enzymes and screening method
US20090155829A1 (en) 2007-12-18 2009-06-18 General Electric Company Heme choline esters and uses thereof
WO2014128726A2 (en) 2013-02-22 2014-08-28 Biogenomics Limited Process for high efficiency refolding of recombinant proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902918B1 (en) * 1998-05-21 2005-06-07 California Institute Of Technology Oxygenase enzymes and screening method
WO2001072999A1 (en) 2000-03-27 2001-10-04 California Institute Of Technology Expression of functional eukaryotic proteins
US20090155829A1 (en) 2007-12-18 2009-06-18 General Electric Company Heme choline esters and uses thereof
WO2014128726A2 (en) 2013-02-22 2014-08-28 Biogenomics Limited Process for high efficiency refolding of recombinant proteins

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
Aumiller W et al "Coupled Enzyme Reactions Performed in Heterogeneous Reaction Media: Experiments and Modeling for Glucose Oxidase and Horseradish Peroxidase in a PEG/Citrate Aqueous Two-Phase System", dx.doi.org/10.1021/jp501126v | J. Phys. Chem. B 2014, 118, 2506-2517.
Bagshawe KD "Antibody-directed enzyme prodrug therapy (ADEPT ) for cancer", Expert Rev. Anticancer Ther. 6 (10), 1421-1431 (2006).
Bradford M "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", Analytical Biochemistry 72, 248-254 (1976).
Cabrita L D et al: "Protein Expressino and Refolding—A Practical Guide to Getting the Most out of Inclusion Bodies", Biotechnology Annual Review, Elsevier, NL, vol. 10, No. Spec. Issue, Jan. 1, 2004.
Capone S et al "Glyco-variant library of the versatile enzyme horseradish peroxidase", Glycobiology vol. 24 No. 9 pp. 852-863, 2014.
Eggenreich B et al "Production strategies for active heme-containing peroxidases from E. coli inclusion bodies—a review", Biotechnology Reports 10 (2016) 75-83.
Ferre H et al: "A Novel System for Continuous Protein Refolding and On-Line Capture by Expanded Bed Adsorption", Protein Science, Wiley, US, vol. 14, No. 8, Aug. 1, 2005.
Gajhede M et al "Crystal structure of horseradish peroxidase C at 2.15 A resolution", nature structural biology, vol. 4 No. 12, Dec. 1997.
Gebauer et al "Engineered protein scaffolds as next-generation antibody therapeutics", Current Opinion in Chemical Biology, vol. 13, Issue 3, Jun. 2009, pp. 245-255, Abstract only.
Gundinger T et al "A comparative approach to recombinantly produce the plant enzyme horseradish peroxidase in Escherichia coli", Journal of Biotechnology 248 (2017) 15-24.
Hnasko R.M.—ELISA—Methods and Protocols; Methods in Molecular Biology, series Editor John M. Walker (DOI 10.1007/978-1-4939-2742-5); Chapter 4 on "Bioconjugation of Antibodies to Horseradish Peroxidase (HRP)", pp. 43-50 (total pages 220). (Year: 2015). *
Humer D, Spadiut O "Improving the Performance of Horseradish Peroxidase by Site-Directed Mutagenesis", Int. J. Mol. Sci. 2019, 20, 916.
Humer et al., "Scalable High-Performance Production of Recombinant Horseradish Peroxidase from E. coli Inclusion Bodies", International Journal of Molecular Sciences, Jun. 29, 2020, vol. 21, No. 13, p. 4625, DOI: 10.3390/ijms21134625.
Jin R et al "Enzymatically Crosslinked Dextran-Tyramine Hydrogels as Injectable Scaffolds for Cartilage Tissue Engineering", Tissue Engineering: Part A vol. 16, No. 8, 2010, 2429-2440.
Josephy PD et al "The Horseradish Peroxidase-catalyzed Oxidationof 3,5,3′,5′-Tetramethylbenzidine", The Journal of Biological Chemistry, vol. 257, No. 7, Issue of Apr. 10, pp. 3669-3675, 1982.
Le Thanh Mai Pham et al; "Optimized refolding and characterization of S-peroxidase (CWPO C of) expressed in", Protein Expression and Purification, vol. 80, No. 2, Jan. 1, 2011.
Lin Meng-I et al: "High yield production of fungal manganese peroxidases by E. coli through soluble expression, and examination of the activities", Protein Expression and Purification, Academic Press, San Diego, CA, vol. 145, Jan. 2, 2018.
Linde D et al "Heterologous expression and physicochemical characterization of a fungal dye-decolorizing peroxidase from Auricularia auricula-judae", Protein Expression and Purification 103 (2014) 28-37.
Morawski B et al "Functional Expression and Stabilization of Horseradish Peroxidase by Directed Evolution in Saccharomyces cerevisiae", Biotechnology and Bioengineering, vol. 76, No. 2, Sep. 2001.
Pham LTM et al "Optimized refolding and characterization of S-peroxidase (CWPO_C of Populus alba) expressed in E. coli", Protein Expression and Purification 80 (2011) 268-273.
Rengarajan et al "Quantifying DNA concentrations using fluorometry: A comparison of fluorophores", Molecular Vision 2002; 8:416-21.
Rice P et al "EMBOSS: The European Molecular Biology Open Software Suite", TIG Jun. 2000, vol. 16, No. 6.
Ryan B et al "Effects of single mutations on the stability of horseradish peroxidase to hydrogen peroxide", Biochimie 89 (2007) 1029-1032.
Simpson R "Estimation of Free Thiols and Disulfide Bonds Using Ellman's Reagent", CSH Protocols; 2008; doi:10.1101/pdb.prot4699.
Smith et al, "Expression of a Synthetic Gene for Horseradish Peroxidase C in Escherichia coli and Folding and Activation of the Recombinat Enzyme With CA2+ and Heme", Journal of Biological Chemistry, American Soceity for Biochemistry and Molecular Biology, US, vol. 265, No. 22, Aug. 5, 1990.
Tatsumi K et al "Removal of Chlorophenols from Wastewater by Immobilized Horseradish Peroxidase", Biotechnology and Bioengineering, vol. 51, pp. 126-130 (1996).
Tupper J et al "In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer", Cancer Gene Therapy (2010) 17, 420-428.
Tupper J et al "Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol", British Journal of Cancer (2004) 90, 1858-1862.
Vasileva N et al "Application of immobilized horseradish peroxidase onto modified acrylonitrile copolymer membrane in removing of phenol from water", International Journal of Biological Macromolecules 44 (2009) 190-194.
Welinder K "Superfamily of plant, fungal and bacterial peroxidases", Current Opinion in Structural Biology 1992, 2:388-393.
Whitwam R Tien M Ed—Valpuesta Jose M et al: "Heterologous expression and reconstruction of fungal Mn peroxidase", Archives of Biochemistry and Biophysics, Academic Press, US, vol. 333, No. 2, Sep. 15, 1996, Abstract only.
Yamaguchi H et al "Refolding Techniques for Recovering Biologically Active Recombinant Proteins from Inclusion Bodies", Biomolecules 2014, 4, 235-251; doi:10.3390/biom4010235.
Zakharova GS et al "High-yield reactivation of anionic tobacco peroxidase overexpressed in Escherichia coli ", Protein Expression and Purification 113 (2015) 85-93.

Also Published As

Publication number Publication date
ES3063878T3 (en) 2026-04-21
EP4125985A1 (de) 2023-02-08
US20230122727A1 (en) 2023-04-20
WO2021191253A1 (en) 2021-09-30
CN115427058A (zh) 2022-12-02
JP7671077B2 (ja) 2025-05-01
EP4125985C0 (de) 2026-01-07
EP4125985B1 (de) 2026-01-07
JP2023519369A (ja) 2023-05-10

Similar Documents

Publication Publication Date Title
Cheng et al. Selenocysteine insertion at a predefined UAG codon in a release factor 1 (RF1)-depleted Escherichia coli host strain bypasses species barriers in recombinant selenoprotein translation
Cao et al. Reconstitution of the mitochondrial PrxIII antioxidant defence pathway: general properties and factors affecting PrxIII activity and oligomeric state
Nordhoff et al. Folding of the four domains and dimerization are impaired by the Gly446. fwdarw. Glu exchange in human glutathione reductase. Implications for the design of antiparasitic drugs
Cherney et al. Structure–activity characterization of sulfide: quinone oxidoreductase variants
CN110023328B (zh) 用于蛋白质表达和递送的组合物和方法
Puchkaev et al. The Sulfolobus solfataricus electron donor partners of thermophilic CYP119: an unusual non-NAD (P) H-dependent cytochrome P450 system
Unterweger et al. Engineering of Aerococcus viridans L-lactate oxidase for site-specific PEGylation: characterization and selective bioorthogonal modification of a S218C mutant
Yunus et al. Purification of SUMO conjugating enzymes and kinetic analysis of substrate conjugation
Simons et al. Site directed immobilization of glucose-6-phosphate dehydrogenase via thiol-disulfide interchange: Influence on catalytic activity of cysteines introduced at different positions
van Lis et al. Heterologously expressed arsenite oxidase: a system to study biogenesis and structure/function relationships of the enzyme family
Drosou et al. Mutations in the docking site for cytochrome c on the Paracoccus heme aa3 oxidase: electron entry and kinetic phases of the reaction
Jiang et al. Comparative study of the insoluble and soluble Ulp1 protease constructs as carrier free and dependent protein immobilizates
Kohlstädt et al. Heterologous production, isolation, characterization and crystallization of a soluble fragment of the NADH: ubiquinone oxidoreductase (complex I) from Aquifex aeolicus
EP4125985B1 (de) Verfahren zur herstellung von hämoperoxidasen
Lüke et al. Biosynthesis of the respiratory formate dehydrogenases from Escherichia coli: characterization of the FdhE protein
Saska et al. Tuning O2 enzymatic reduction: Roles of methionine-rich domains and electrochemical metalation of active centers
Jeon et al. New insights into the mechanism of nickel insertion into carbon monoxide dehydrogenase: analysis of Rhodospirillum rubrum carbon monoxide dehydrogenase variants with substituted ligands to the [Fe3S4] portion of the active-site C-cluster
Lacey et al. Characterization of mitochondrial thioredoxin reductase from C. elegans
EP3884956A1 (de) Verfahren zur herstellung von hämperoxidasen
US12460214B2 (en) Polypeptides with peroxidase activity
Xin et al. Structural and catalytic alteration of sarcosine oxidase through reconstruction with coenzyme-like ligands
Tong et al. Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein
EP3885436A1 (de) Polypeptide mit peroxidaseaktivität
Matsumoto et al. Site-specific tetrameric streptavidin-protein conjugation using sortase A
AU2023390556A1 (en) Uricase conjugates and methods of use thereof

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: TECHNISCHE UNIVERSITAET WIEN, AUSTRIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUMER, DIANA;SPADIUT, OLIVER;EBNER, JULIAN;SIGNING DATES FROM 20220920 TO 20220922;REEL/FRAME:061333/0142

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE